 
 
 
A Team -Based and Technology -Driven Adherence 
Intervention to Improve Chronic Disease Outcomes  
Short Title: Adherence Wizard  
 
Protocol Number: A16- 691 
 
National Clinical Trial (NCT) Identified Number:  [STUDY_ID_REMOVED] 
 
Principal Investigator:  Dr. JoAnn Sperl -Hillen   
 
Funded by : National Heart, Lung, Blood Institute, National Institutes of Health  
 
Version Number:  v. 6.0 
 
12th February 2021
Table of Contents  
STATEMENT OF COMPLIANCE  ............................................................................................................................. 1 
1 PROTOCOL SUMMARY  ............................................................................................................................... 1 
1.1 Synopsis  ................................................................................................................................................ 1 
1.2 Schema ................................................................................................................................................. 3 
1.3 Schedule of Activities (SoA)  ............................................................................................................... 4 
2 INTRODUCTION  ............................................................................................................................................ 5 
2.1 Study Rationale  .................................................................................................................................... 5 
2.2 Background ........................................................................................................................................... 5 
2.3 Risk/Benefit Assessment  .................................................................................................................. 10 
2.3.1  Known Potential Risks  ................................................................................................... 10 
2.3.2  Known Potential Benefits  .............................................................................................. 10 
2.3.3  Assessment of Potential Risks and Benefits  .............................................................. 10 
3 OBJECTIVES AND ENDPOINTS  .............................................................................................................. 10 
4 STUDY DESIGN  ........................................................................................................................................... 12 
4.1 Overall Design  .................................................................................................................................... 12 
4.2 Scientific Rationale for Study Design .............................................................................................. 13 
4.3 Justification for Dose  ......................................................................................................................... 13 
4.4 End of Study Definition  ..................................................................................................................... 13 
5 STUD Y POPULATION  ................................................................................................................................ 13 
5.1 Inclusion Criteria  ................................................................................................................................ 13 
5.2 Exclusion Criteria  ............................................................................................................................... 14 
5.3 Lifestyle Considerations  .................................................................................................................... 14 
5.4 Screen Failures  .................................................................................................................................. 14 
5.5 Strategies for Recruitment and Retention  ...................................................................................... 14 
6 STUDY INTERVENTION ............................................................................................................................ 15 
6.1 Study Intervention(s) Administration  ............................................................................................... 15 
6.1.1  Study Intervention Description  ..................................................................................... 15 
6.1.2  Dosing and Administration  ............................................................................................ 16 
6.2 Preparation/Handling/Storage/Accountability  ................................................................................ 16 
6.2.1  Acquisition and accountability  ...................................................................................... 16 
6.2.2  Formulation, Appearance, Packaging, and Labeling  ................................................ 16 
6.2.3  Product Storage and Stability  ....................................................................................... 16 
6.2.4  Preparation  ...................................................................................................................... 16 
6.3 Measures to Minimize Bias: Randomization  .................................................................................. 17 
6.4 Study Intervention Compliance ........................................................................................................ 17 
6.5 Concomitant Therapy  ........................................................................................................................ 17 
6.5.1  Rescue Medicine  ............................................................................................................ 18 
7 STUDY INTERVENTION DISCONTINUATION AND PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  .................................................................................................................... 18 
7.1 Discontinuation of Study Intervention  ............................................................................................. 18 
7.2 Participant Discontinuation/Withdrawal  from the Study  ............................................................... 18 
7.3 Lost to Follow -Up ............................................................................................................................... 18 
8 STUDY ASSESSMENTS AND PROCEDURES  ..................................................................................... 18 
8.1 Efficacy Assessments  ....................................................................................................................... 18 
8.2 Safety and Other Assessments  ....................................................................................................... 18 
8.3 Adverse Events and Serious Adverse Events  ............................................................................... 18 
8.3.1  Definition of Adverse Events (AE)  ............................................................................... 19 
8.3.2  Definition of Serious Adverse Events (SAE)  .............................................................. 19 
8.3.3  Classification of an Adverse Event  .............................................................................. 19 
8.3.4  Time Period and Frequency for Event Assessment and Follow -Up ....................... 20 
8.3.5  Adverse Event Reporting  .............................................................................................. 20 
8.3.6  Serious Adverse Event Reporting  ............................................................................... 20 
8.3.7  Reporting Events to Participants  ................................................................................. 20 
8.3.8  Events of Special Interest  ............................................................................................. 21 
8.3.9  Reporting of Pregnancy  ................................................................................................ 21 
8.4 Unanticipated Problems  .................................................................................................................... 21 
8.4.1  Definition of Unanticipated Problems (UP)  .................................................................  21 
8.4.2  Unanticipated Problem Reporting  ................................................................................ 21 
8.4.3  Reporting Unanticipated Problems to Participants  ................................................... 22 
9 STATISTICAL CONSIDERATIONS .......................................................................................................... 22 
9.1 Statistical Hypotheses  ....................................................................................................................... 22 
9.2 Sample Size Determination  .............................................................................................................. 23 
9.3 Populations for Analyses  .................................................................................................................. 23 
9.4 Statistical Analyses ............................................................................................................................ 23 
9.4.1  General Approach  .......................................................................................................... 23 
9.4.2  Analysis of the Primary Efficacy Endpoint(s)  ............................................................. 24 
9.4.3  Analysis of the Secondary Endpoint(s)  ....................................................................... 25 
9.4.4  Safety Analyses  .............................................................................................................. 26 
9.4.5  Baseline Descriptive Statistics  ..................................................................................... 26 
9.4.6  Planned Interim Analyses  ............................................................................................. 26 
9.4.7  Sub-Group Analyses  ..................................................................................................... 27 
9.4.8  Tabulation of Individual participant Data  .................................................................... 27 
9.4.9  Exploratory Analyses  ..................................................................................................... 27 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  .............................. 27 
10.1  Regulatory, Ethical, and Study Oversight Considerations  ........................................................... 27 
10.1.1  Informed Consent Process  ........................................................................................... 28 
10.1.2  Study Discontinuation and Closure  ............................................................................. 28 
10.1.3  Confidentiality and Privacy  ........................................................................................... 29 
10.1.4  Future Use of Stored Specimens and Data  ............................................................... 31 
10.1.5  Key Roles and Study Governance  .............................................................................. 31 
10.1.6  Safety Oversight  ............................................................................................................. 32 
10.1.7  Clinical Monitoring  .......................................................................................................... 33 
10.1.8  Quality Assurance and Quality Control  ....................................................................... 33 
10.1.9  Data Handling and Record Keeping  ............................................................................ 33 
10.1.10  Protocol Deviations  ........................................................................................................ 34 
10.1.11  Publication and Data Sharing Policy  ........................................................................... 34 
10.1.12  Conflict of Interest Policy  .............................................................................................. 34 
10.2  Additional Considerations  ................................................................................................................. 35 
10.3  Abbreviations  ...................................................................................................................................... 36 
11 REFERENCES  ............................................................................................................................................. 38 
 
STATEMENT OF COMPLIA NCE  
The trial will be carried out in accordance with International Conference on Harmonisation Good Clinical 
Practice  (ICH GCP) , United States (US) Code of Federal Regulations (CFR) applicable to clinical studies (45 
CFR Part 46, 21 CFR Part 50, 21 CFR Part 56, 21 CFR Part 312, and/or 21 CFR Part 812) , and the National 
Heart, Lung, Blood Institute, National Institutes of  Health Research Terms and Conditions of Award.  
 
National Institutes of Health ( NIH)-funded investigators and clinical trial site staff who are responsible 
for the conduct, management, or oversight of NIH -funded clinical trials  have completed Human Subject s 
Protection and ICH GCP Training.  
 
The protocol, informed consent form(s), recruitment materials, and all participant materials will be submitted to the Institutional Review Board ( IRB) for review and approval.  Approval of both the 
protocol and the consent form (s) (or waiver of consent ) must be obtained before any participant is 
enrolled.  Any amendment to the protocol will require review and approval by the IRB before the 
changes are i mplemented to the study.  In addition, the IRB will determine whether  a new consent is 
needed based on the approved protocol changes and make a determination regarding whether a  recall 
needs to be obtained from participants who were previously waivered or provided consent . 
1  PROTOCOL SUMMARY  
1.1 SYNOPSIS  
Title:  A Team -Based and Technology -Driven Adherence Intervention to Improve 
Chronic Disease Outcomes  
Study Des cription : More than 50% of adults treated for diabetes, hypertension, or lipid 
disorders have suboptimal medication adherence, a prominent barrier to 
continued improvement in chronic disease care in the United States. Primary 
care providers (PCPs) often fail to identify medication nonadherence and/or have insufficient time and training to address u nderlying reasons for it. In 
this project, we propose a patient -centered and technology -driven strategy 
to identify patients with adherence issues and apply a team approach that will help them achieve evidence -based personalized goals for glucose, blood 
pressure  (BP), or lipids . The study is a two -arm pragmatic patient 
randomized trial at 28 primary care clinics targeting adult patients not 
meeting recommended goals for BP, A1C, or statin use  with poor medication 
adherence.  
Objectives:  
 (1) Identify and address nonadherence for adults with chronic diseases; (2) 
Improve management of previously uncontrolled blood pressure, blood sugar, and lipid disorders; and (3) Increase patient involvement in 
medication decision making.   
Endpoints:  Primary Endpoint:  (a) For each condition, achievement of an Epic generated 
proportion of days covered (e- PDC) ≥80%  for all medication classes for that 
particular condition (diabetes, hypertension, statin indication) in the 12 months following index date. (b) Mean change in systolic blood pressure 
(SBP) from the last BP within the 12 months prior to the index visit, to  the 
last BP value within 12 months after the index visit. (c) Change in A1C value from the last lab test within 12 months prior to the index visit to the last lab 
test within 12 months after the index visit.  
Secondary Endpoints: cost and cost effectivenes s of the intervention . 
Tertiary Endpoints: (a) t otal 10 -year  American College of 
Cardiology/American Heart Association  (ACC/AHA ) Cardiovascular ( CV) risk, 
(b) patient reported medication adherence using a validated  survey  
instrument , (c) Patient and provider  experience and  satisfaction , (d) 
facilitators and barriers to implementation of the intervention  
Study Population:  The study includes  adult patients from  at least 2 8 HealthPartners  Medical 
Group (HPMG)  primary care clinics  (HealthPartners  (HP) a nd Park Nicollet 
(PN)  in Minnesota .   
Phase:  3 
Description of 
Sites/Facilities 
Enrolling Participants:  The study will take place at HP and PN primary care c linics who are part of a  
large integrated care system throughout Minnesota and Wisconsi n. Clinics to 
be enrolled in the study ha d an affiliation with one of three retail pharmacy 
chains  (HP, PN and Goodrich pharmacies)  at the time the study started .  A 
pharmacy affiliation is described as a pharmacy that wa s located in a HP or 
PN clinic.  
Description of Study 
Intervention: A clinical decision support (CDS) system for CV risk -factor control will be  
enhanced to support a team -based care model that does the following: (a) 
identifies patients not achieving opt imal outcomes for BP , lipid, and glucose 
management, (b) assesses  medication adherence information  for these 
patients (c)  incorporates adherence information into the clinical decision 
support tools available at the point of care (d) creates a patient registry that 
facilitates  proactive pharmacist outreach  for patients with potential 
adherence issues identified , and (e) coordinates action plans  between 
pharmacists and other providers on the care team  to address adherence 
issues . 
Study Duration:  60 months  
Participant Duration:  12 months  minimum follow up after an index visit  for a range  of 12-18 
months  follow up.  
 
  
1.2 SCHEMA  
 
Identification  
Of Target  
Patients   
    Randomize  
 
 
   CDS 
Intervention  
  ReachOut   
Intervention  
  Patient  
Follow -up 
    Outcomes  
Assessed  
12 M onths  
Post Index V isit 
      
 
  No Pharmacist phone 
intervention . 
  
Intervention  
 
 
 
 Control  
Pharmacist phone intervention based on IMB 
(information/motivation/beliefs) model and adherence 
action plan initiated  for patients with persistent low 
adherence and unmet clinical outcomes.  Randomize patients at study clinics  
No Pharmacist follow -
up. 
 Basic CDS without 
adherence information.  
 
Action plan documented within EHR and incorporated into 
subsequent point of care CDS. Pharmacist follows -up 
according to Action Plan developed .  
 Enhanced CDS with medication adherence alerts to patients 
and providers.  
• e-PDC ≥80% for all BP, glycemic and statin medications   
• Change  in systolic BP and A1C values  from baseline  
• Cost of delivering the intervention and the incremental medical care costs attributable to  the 
intervention. Impact of the intervention on health outcomes and its cost -effectiveness  CDS system runs at all primary care visits of adults aged 18 -75 that identifies patients 
with suboptimal control and potential medication adherence issues for BP, lipids, and 
glycaemia medications.  
 
1.3 SCHEDULE OF ACTIVITIES (SOA)  
 
Procedures  
Pre-Index  Visit  
Index Visit – first 
eligible visit with 
primary care  
0 to 6 months  after 
Index visit  
6 to 12 months 
after index visit  
12 to 18 months 
after index visit  
Select study clinics  X     
EHR data is exchanged with Wizard web service  in 
the background at the patient’s first and subsequent 
primary care encounters  occurring during the study 
duration . An encounter -based limited data set is 
collected and stored in a data repos itory 
(intervention & control)   X X X X X 
All eligible patient s are randomly assigned a study 
identification (ID)  the first time they are eligible for 
CDS at a study clinic   X    
Based on the study ID, a n eligible patient is then 
randomly assigned  to adherence  intervention or 
control   X    
After Wizard determines study eligibility and CDS 
recommendations, it prompts CDS tools to be printed for the intervention -assigned patient  and 
their provider through a Best Practice Advisory (BPA) 
for rooming staff at each primary care encounter 
during the study period   X X X X 
The eligible intervention -assigned  patient has an 
attempted exposure  to Adherence CDS at each 
primary care encounter during the study period   X X X X 
Wizard algorithms are run outside of encounters on 
all study eligible patients at set intervals (6, 12, and 18 months) for analysis purposes.  A  limited data set 
is collected and stored in a data repos itory 
(intervention & control  patients )   X X X 
An eligible  intervention -assigned  patient i s added to 
a pharmacist outreach intervention registry if study 
criteria are still met (not at goal and not adherent)    X   
An eligible  intervention -assigned  patient is assigned 
to a pharmacist    X   
Pharmacist calls eligible  patient  (multiple attempts)  
for adherence assessment and action plan     X  
Pharmacist follow -up per action plan     X X 
Experience and satisfaction surveys sent to a random 
group of  patients (intervention & control)    X X  
Procedures  
Pre-Index  Visit  
Index Visit – first 
eligible visit with 
primary care  
0 to 6 months  after 
Index visit  
6 to 12 months 
after index visit  
12 to 18 months 
after index visit  
Safety monitoring per Data Safety Monitoring Board 
(DSMB)  plan (intervention & control)  X X X X X 
 
2  INTRODUCTION  
2.1 STUDY R ATIONALE   
More than 50% of adults treated for diabetes, hypertension, or lipid disorders have suboptimal 
medication adherence, a prominent barrier to continued improvement in chronic disease care in the United States  (US) . Primary care providers (PCPs) often fail to identify medication nonadherence and/or 
have insufficient time and training to address underlying reasons for it. In this project, we propose a 
patient -centered and technology -driven strategy to identify patients with adherence issues and apply a 
team approach to help them achieve evidence -based personalized goals for glucose, blood pressure, or 
lipids. This intervention extends the use of a widely available clinical decision support (CDS) 
infrastructure to support a model of care that  will integrate pharmacists within the primary care team. 
The intervention relies on a continuous health informatics loop to do the following: (a) identify poor adherence to medications ; (b) establish and maintain a  registry of patients identified for proactive 
pharmacist outreach; (c) implement a pharmacist outreach s trategy based on an 
information/motivation/behavioral (IMB) framework recommended by the World Health Organization 
(WHO) with demonstrated ability to influence adherence across a variety of clinical applications; and (d) 
coordinate care and adherence information by incorporating pharmacist assessment and action plans into CDS at subsequent office encounters.  
2.2 BACKGROUND   
The Consequences of Medication Nonadherence  
Medication adherence has been shown to be suboptimal across multiple chronic disease states1-4 and is 
a key factor that affects clinical outcomes.2,5-11 It is estimated that 50% of chronic disease medications 
are not taken as prescribed,12 leading to compromised health, increased hospitalizations an d mortality, 
and serious economic consequences.3,9,13- 22 Medication non -adherence costs the US $258 to $290 billion 
annually, thus contributing substantially to the current health care cost crisis23-25. The clinical 
consequences of medication non -adherence include an estimated 125,000 deaths a year, and 
contributes to millions of potentially preventable hospital admissions each year.3,26,27  
Determinants of poor medicatio n adherence are complex and include health system, social/economic, 
therapy -related, condition -related, and patient -related factors.28,29 Because nonadherence involves a 
complex cluster of behaviors, many different constructs have been developed to identify patients  and 
quantify problems related to patients who have been prescribed a drug and have not filled a 
prescription  or are not using the drug as prescribed, whether intentionally or non -intentionally .30-35 
Challenges of Measuring Nonadherence  
In outpatient settings, patient self -reported medication adherence measurements can be time 
consuming to obtain, are s ubject to recall bias and overestimation of adherence, and have a propensity 
to elicit socially acceptable responses that may not correlate well with refill and administrative 
measures.36,37Objective measures of adherence derived from administrative claims and electronic 
medical record (EMR) data are more efficient and less biased. A variety of such measures have been 
develope d,38  and standard ized terminology and definitions have recently been advocated.39 The 
Proportion of Days Covered (PDC) has been operationalized and endorsed by the Pharmacy Quality 
Alliance and introduced by the Centers for Medicare & Medicaid Services (CMS) as a quality metrics tool 
to assess secondary adherence related to  hypoglycemi c, antihypertensive, and cholesterol -lowering 
drugs.  The PDC reduces overestimation of adherence, eliminates potential recall bias associated with 
patient self -report, and provides a conservative estimate of the highest possible level of medication 
consump tion.38,40 For this study, limitations of PDC include (a) the data is only available for patients with 
claims data through HealthPartners insurance, and (b) PDC is not useful for calculating primary 
nonadherence (a medication prescribed  but never filled) because the prescribed medication will not be 
identified in claims data.39  
In the 2018 version of Epic (Epic Systems Corporation), a measure of adherence similar to a calculated 
PDC is made available at encounters based on the total number of days supplied for a specified measurement period of time (default time being 6 months) prior to a clinical enco unter. According to 
Epic, ‘Medication adherence is determined by comparing a patient's current outpatient medication list in Epic with the number of times a medication has been dispensed.’
41 In Epic, PDC  is expressed as the 
percent of days in the measurement period before the encounter covered by medication fills for a specific medication based on data from Surescripts, an information technology company that supports e-prescription with the most comprehensive prescription dispense data in the United Sates. An indicator 
of confidence in the e-PDC (high, medium, or low) is also determined and displayed with the e-PDC 
score based on a determination of how accurate or reliable the Surescripts data is.  The confidence is 
high if a patient fills all their prescribed medications from a pharmacy that reports all their dispense data 
to Surescripts; medium if high criteria is  not met but there is some dispense and claims data available; 
low if a patient fills their prescribed medications from different pharmacies, some of which do not 
report to Surescripts and no claims data is available
41.   
For this intervention, the Epic pre -calculated PDC score has the advantage of being available for most 
patients seen in the care system rather than being limited to a subset of patients with HealthPartners insurance claims data available , which would be the case if we were to calcul ate PDC ourselves in the 
traditional methods using claims data. Because of the clinical advantages of e-PDC over calculated PDC, 
the MAS has been chosen for this study as the objective measure of medication adherence for intervention and study outcomes.  
The New Care Paradigm includes Pharmacists  
When medications are prescribed and monitored, physicians often fail to communicate and discuss with 
patients critical elements about medication use.  Thus, the adherence problem will be hard to solve by expecting m ore adherence and medication counseling to be done by physicians who often lack the time 
and may lack appropriate training to provide adherence counseling
42-45. Previous research shows that 
community -based pharmacists are well- trained and well- positioned to provide medication support for 
people with chronic conditions.46,47 A 2011 report to the US Surgeon General urged moving beyond 
research to widespread implementation and adoption of a care model that embraces embedded 
pharmacist services.48 Since 2004, pharmacist licensure requires a Doctor of Pharmacy degree, which is a 
four -year academic program designed to ensure competency of pharmacists as medication managers. 
Pharmacists coming out of training are eager to provide these enhanced services with 95% of student pharmacists believing that providing clin ical services is important and 87% believing that clinical care 
opportunities exist for them in the workplace.49 Opportunities for clinical care involvement are growing 
nationally with many rigorous demonstrations of the clinical and economic value of pharmacists. 49-55 
HealthPartners has also embraced the expanded role of pharmacists and we have shown in a 
randomized trial that home BP telemetry with pharmacist case management significantly improved BP control in hypertensive adults compared with usual care after 6 and 12 months.
50 A recent meta -
analyses supports the ability of pharmacis ts, alone and as part of a team -based care model, to improve 
medication adherence and control of hypertension51 and CV risk factors in patients with and without 
diabetes. There are numerous other examples of coordinated care models in the US that have removed barriers to pharmacist participation: (1)The Asheville Project model which began in 1997 incorporated fee for service payments from  employers to pharmacists and saved North Carolina $13 million.
52,53 The 
model was expanded within the US through the 10 -City Diabetes Challenge Project in 2007.54 (2) The 
Wisconsin TEAM Trial demonstrated the ability of pharmacists to improve medication adherence and BP control in patients with hypertension.
55 (3) The Pennsylvania Project demonstrated that community 
pharmacists improved PDC for 5 targeted medication classes and reduced total health care costs ($241 
for patients taki ng statins; $341 for patients taking diabetes medications).56 
The Joint Pharmacist Organization Committee representing over 100,000 pharmacists across a spectrum 
of practice settings is actively involved in policy decisions to ensure that pharmacist payment structures keep pace with the evolving value -based health care system and pharmacy profession.
57  Patient -
centered medical homes (PCMH) within the Veterans Affairs (VA) Health Care System and Maine PCMH are examples of how pharmacists can be used within value -based payment models.
58 The 2016 CMS 
Transforming Clinical Practice Initiative creates US networks to promote t he establishment of 
community based health teams to support chronic care management.59  
Pharmacists are perhaps the most accessible of all health professionals and are routinely ranked as one of the most trusted profession als in the United States.
60,61 Further, patients are more willing to follow 
through with prescriber recommendations when reinforced by pharmacistss.62  With growing 
pharmacist access to the EMR, integration of pharmacists into the care workflow, and stronger communication with prescribers, there is reason to expect a substantive favorable effect of increased 
pharmacist involvement on medication adherenc e and on chronic disease outcomes.
63-65 
Clinical Decision Support Systems  
EMR -based CDS systems initially were limited to prompts and reminders, which had a favorable impact 
on ordering of tests and procedures but failed to improve intermediate outcomes of care such as BP, 
glucose, or lipid control.66 However, in the last decade, EMR -based CDS systems have become much 
more sophisticated and have been shown to improve BP and glucose control and other intermediate outcomes of ca re in numerous studies.
67-70 However, to date, only a  few integrated health systems that 
include both claims and clinical data (e.g., Kaiser) have been able to incorporate medication adherence 
data into the EMR and use those data in a sustained way.71 Furthermore, incorporation of adherence -
related data into EMR dashboards and CDS tools thus far has not been shown to have a significant 
impact on clinical outcomes.72 This is not surprising, because prescribers often lack the time and training 
to skillfully address medication adherence issues in the context of a visit. In fact, some research suggests that prescribers supply vital information abo ut new prescriptions less than 30% of the time.
44,45 Thus, 
most studies of CDS that include adherence data have been limited in impact by underutilization of the tools and/or unsucc essful reliance on patients to complete adherence barriers assessments through 
patient portals.
72 One obvious improvement opportunity is to integrate pharmacists into the care 
process. However, although it is operationally feasible, most community pharmacists currently do not have access to the EMR so that (a) two -way communication between PCPs and pharmacists is 
inefficient, (b) the prescriber has limited fill data to use for assessing adherence, or is unaware of the 
availability and interpretation of available e -PDC and (c) it is difficult to integrate pharmacists working 
remotely into primary care teams. This project squarely addresses the barriers to integration of pharmacists into primary care teams outside of totall y integrated care systems (about 90% of 
Americans). The challenges are solvable using novel informatics approaches.  In this project, we use an 
established multifunctional CDS system as the cornerstone of an expanded informatics system that (a) 
makes adher ence data available to prescribers at the time of a visit, (b) enables efficient and automatic 
bidirectional communication between pharmacist and prescribers, and (c) directs pharmacist attention 
to the subset of non -adherent, poorly controlled patients wh o are most likely to benefit from 
personalized attention to adherence -related issues.  
The Information -Motivation -Behavior (IMB) conceptual model for the pharmacists’ intervention  
The IMB conceptual model that guides this intervention (Figure below) posits that information is a 
prerequisite for changing behavior but by itself is insufficient to achieve behavior change.73 Motivation is 
also a key determinant for behavior change and has been found to be a key factor in promoting 
adherence to chronic therapies, but the relationship between  motivation and information constructs is 
elastic (a highly informed person may have low motivation and vice versa). Practically, the IMB model 
directs the pharmacist’s attention to the influence of psychosocial factors related to adherence behaviors, incl uding readiness to change, that evolve over time and cannot be addressed by information 
interventions alone. Interventions based on IMB have been effective at influencing behavioral change across a variety of clinical applications, including adherence to a sthma medication and reduction of HIV 
risk behaviors.
74-78 The IMB model incorporates elements of social cognitive theory (the importance of 
self- efficacy), stress coping model (dealing with the stress of the condition), and trans -theoretical model 
(incorporating readiness to change) –  all of which are evidence -based and considered important for 
successful self- management interventions for people chronic disease.79-83 The IMB model has been 
endorsed by the WHO to address adherence problems, with recognition that the presence of both 
motivation and information increases the likelihood of adherence.28,84 
Figure 1: Information -Motivation -Behavior Change Fr amework  
Experience with CDS Development and Implementation  
We previously constructed and evaluated an EMR -based diabetes CDS system to improve outcomes in 
adults with type 2 diabetes in an NIH- funded clinical trial (DK068314). In a randomized trial of 11 clinics 
with 41 consenting PCPs and 2556 eligible diabetes p atients we showed significantly better A1C 
(intervention effect - 0.26%, 95% CI: - 0.06 to - 0.47, P=.014) and systolic BP (intervention effect - 2.64 mm 
Hg, 95% CI: -  0.19 to - 5.10, P=.035) in intervention group than control group patients using a general 
linear mixed -model analysis with repeated time measurements and control for clustering. Low- density 

lipoprotein (LDL) cholesterol improved a mean of 23 mg/dL in both groups but was not superior in the 
intervention group ( P=.63).84,85 Over 94% of PCPs expressed satisfaction with the CDS.86 In subsequent 
National Heart, Lung, and Blood Institute (NHLBI) funding (R01HL102144), we expanded the C DS tool to 
focus on CV risk factor domains, and we improved the workflow and scalability in significant ways.  
The current version of this CDS system is Web -based for more efficient scalability and dissemination to 
other EMR systems, and we prioritize care  recommendations based on potential CV benefits and 
severity of clinical conditions. Moreover, CDS is provided both to the provider and directly to the patient 
in order to promote patient engagement and shared decision making. The patient -directed CDS disp lay 
presents sophisticated risk information in a low literacy and numeracy format.87-90 PCPs use this CDS at 
more than 75% of targeted office visits. The CDS system has now been disseminated to all clinics in 
HPMG (HP and PN) and to 2 large rural care systems and is used on a daily basis in the care of more than 1.5 million patients in four states. Our extensive experience and prior work enables us to immediately 
focus on the substantial enhancements needed to integrate medication adherence data and pharmacist 
outreach components into the underlying CDS system, and to assess impact on care.  
Experience with pharmacists on the care teams  
Pharmacists  have already begun to embrace system wide care strategies to expand the pharmacist role 
to support the care of patients with targeted conditions. Some  pharmacists have bidirectional access to 
the car e system’s EMR in compliance with patient privacy regulations and have already been trained to 
conduct targeted EMR chart reviews, order overdue labs based on standing orders and care protocols, 
and reinforce diabetes clinical goals when processing prescriptions for diabetes medications or supplies. Additionally, some pharmacists use protocol -driven standing orders to adjust hypertension therapy and 
authorize refills for chronic conditions. These pharmacists are enthusiastic about doing clinical work, and 
seek out roles that allow them to focus on patient care. The care system is engaged and supportive of 
this research project and anticipates a more active future role of pharmacists on the care team.  
 Preliminary Pilot Data: Supporting data for this were obt ained from a repository of CDS -generated, 
EMR -based data that included HealthPartners and Park Nicollet affiliated clinics.  We evaluated 26,351 
encounters among 19,976 patients aged 18 -75 from 28 clinics with affiliated pharmacies for the period 
January 1 6, 2019 to April 25, 2019. The data included a comprehensive list of medications (with 
medication identifiers) for BP, lipids, and glycemic control and algorithmically derived information 
related to clinical conditions, lab measures, and e -PDC.  
Table 1. P rimary Care Patients with Chronic Conditions with Adherence Issues Identified, 1/16/19 – 
4/25/19  
Number of patients 
with the condition 
identified at a visit  On 
medication related to the 
condition  Meeting 
clinical eligibility 
criteriaa e-PDC 
confidence moderate/hig
h e-PDC 1-
79%  Primary 
care visit  
Hypertension 
N=13,349  N=12,360 
(93%)  N=2,891 (23%)  N=1,808 
(63%)  N=816 
(45%)  N=684 
(84%)  
Diabetes N=12,158  N=8,827 
(73%)  N=3,385 (38%)  N=2,240 
(66%)  N=1,123 
(50%)  N=983 
(88%)  
On statin N=11,085  N=11,085 
(100%)  N=10,645 
(96%)  N=6,565 
(62%)  N=2,334 
(36%)  N=2,010 
(86%)  
(a) A1C >8%, BP  >140/90 mm Hg on 2 consecutive occasions or meeting ACC/AHA indications for 
moderate or high intensity statins.   
Table 1  indicates the total number of patients identified with hypertension (n=13,349), diabetes 
(n=12,158), or statin use (n=11,085).  Over 11,000 of these patients are not meeting recommended 
clinical goals and 21% to 33% of these have secondary nonadherence is sues identified.  
2.3 RISK/BENEFIT ASSESSM ENT   
2.3.1  KNOWN  POTENTIAL RISKS  
Potential risks to patient participants include the possibility that the intervention may provide treatment 
considerations to PCPs on the basis of the national evidence -based guidelines and /or national standards 
for adherence measurement that may be inappropriate for a given individual patient and, if applied 
without further checking the clinical status of a given patient, could lead to erroneous therapy, adverse 
events, disability, or death . However, the clinical recommendations are evidence -based and 
operationalize current national and regional standards of care; therefore, the risk of untoward consequences of such clinical actions is considered minimal. Moreover, this potential risk is rou tinely 
present in every clinical encounter in the health care system.  
 
2.3.2  KNOWN POTENTIAL BENE FITS  
Patient participants will have no defined personal benefit from participating in this project. Other than surveys  and maybe  interviews  in a sample of study eligible patients , no direct communication between 
research team members and patient participants is planned as  part of the study protocol.  Although 
some patients with  adherence issue and sub-optimally  controlled  cardiovascular risk factors and 
diabetes may be identified better by their care providers as a result of this intervention,  no claim of 
clinical benefit to an individual patient can or will be made.  
 
2.3.3  ASSESSMENT OF POTENT IAL RISKS AND BENEFITS  
The implemen tation of clinical decision support and pharmacist outreach  related to medication 
adherence for chronic disease management poses minimal risk to providers and patients.  The CDS recommendations are concordant with relevant clinical practice guidelines and facilitates provider access to clinically relevant information at the point -of-care.  The CDS intervention training and 
statements on the CDS displayed will reinforce that  providers should exercise their judgement  before 
following any CDS treatment suggest ions. Therefore, patients will be exposed to standard of care.  One 
risk in this study is the potential breach of privacy, for which appropriate measures have been taken to 
mitigate the possibility of such risk.  The potential for these interventions to improve clinical outcomes and increase medication adherence for patients with suboptimally controlled chronic conditions has important public health implications that outweigh the potential risks.  
 
3 OBJECTIVES AND ENDPO INTS  
 
OBJECTIVES  
What are we 
measuring  ENDPOINTS  
How are we measuring it?  JUSTIFICATION FOR ENDPOINT S 
Primary    
1.  Impact of the 
intervention on 
blood pressure  
medication 
adherence and 1. We will assess  patient achievement 
of (a) a n e-PDC ≥80% for all BP 
medications  and (b) a reduction in 
systolic BP .  (Time Frame is 12- month 
period after an index office visit. )  The e-PDC has been operationalized 
by the Epic (Epic Systems Corporation) and made readily 
available in their 2018 EMR version. 
This e-PDC is available for 
OBJECTIVES  
What are we 
measuring  ENDPOINTS  
How are we measuring it?  JUSTIFICATION FOR ENDPOINT S 
systolic blood 
pressure  control  
 
2.  Impact of the intervention on non -
insulin glycemic  
medication adherence  and A1C 
control  
 3. Impact of the intervention on statin  medication 
adherence  
 
  
2. We will assess  patient achievement 
of (a) e-PDC≥80% for all non -insulin 
glycemic medications and (b) a 
reduction in A1C values . Time Frame 
is 12 -month period after an index 
office visit.  
  
3. We will assess patient achievement 
of an e-PDC ≥80% for a statin  
medication.  (Time Frame is 12-
month period after an index office 
visit) prescription medication and provides 
current levels of adherence as well as a measure of the quality of data used to calculate the score expressed as the confidence level. The e -PDC 
reduces overestimation of 
adherence, eliminates potential 
recall bias asso ciated with patient 
self- report, and provides a 
conservative estimate of the highest possible level of medication 
consumption per the available data 
at the moment.      
 
Systolic blood pressure, A1C, and 
statin use  are intermediate variables 
strongly associated with morbidity 
and mortality related to the 
associated clinical domains.    
Secondary    
1. Impact of the 
intervention  on 
overall healthcare 
costs  
 2. Predicted long -
term health impact and c ost-
effectiveness  of the 
intervention  from 
the health system 
(payer) perspective  
 
 1. We will measure the cost of 
delivering the intervention using micro -cost accounting methods and 
the incremental medical care costs attributable to the intervention, defined from the healt h system 
perspective, measured using 
insurance claims incurred in the 
median 12 -month pre - and post -
index date periods by participants 
with an affiliated HealthPartners insurance plan  in each study group.  
 2. We will use a cardiovascular 
disease microsimulation model to 
predict the impact of the intervention 
on health outcomes and its cost -
effectiveness, defined from the 
health system perspective, over up to 
a 30 -year prospective time horizon.  
 1. If the intervention is found to be 
effective, the cost of delivering the 
intervention and its incremental effect on medical care utilization will be important outcomes to informing dissemination and implementation to other systems and settings.  
 
2. A full measurement of the value of 
the intervention canno t be observed 
during the study period, but validated microsimulation methods 
can be used to estimate the full 
impact of the intervention on preventing or delaying incidence of disease and in averting future medical care costs —both of which 
will be importan t to inform the 
translation and adoption of the intervention, if found to be effective.  
Tertiary/ Exploratory    
OBJECTIVES  
What are we 
measuring  ENDPOINTS  
How are we measuring it?  JUSTIFICATION FOR ENDPOINT S 
1. The impact of the 
intervention on 
10-year CV risk  
2. Survey assessed 
patient reported adherence  
3. Patient and 
provider experience and satisfaction  
4. Qualitative analysis of CDS user experience  1. We will assess reduction in 10 -
year CV risk  measured at each 
encounter  
2. We will conduct phone  surveys 
on a random sample of up to 
1400 eligible  patients 
approximately  2-4 we eks after an 
index visit  and subsequent ly ~6 
months later (after a phone 
outreach has occur red) 
3. We will survey all providers and pharmacists approximately 6 -12 
months after implementation  
4. We may  conduct e nd user 
interviews  The CDS assesses  and prioritizes CV 
risks factors according to the 
percentage of 10 -year CV risk that 
can be reduced if actions are taken to address the risk factor.  
 
Provider and patient experience and 
satisfaction information provide end -
user opinions of the intervention which helps to assess impact and improve the product.  
 
4 STUDY DESIGN  
4.1 OVERALL  DESIGN  
• A statement of the hypothesis:  Poor adherence to medications for chronic diseases is common, 
but providers often fail to identify patients with adherence issues and/or lack adequate time to address them. We hypothesiz e that the intervention will proactively (1) identify and address 
nonadherence for adults with chronic diseases; (2) improve management of previously 
uncontrolled blood pressure, blood sugar, and lipid disorders; (3) increase patient involvement 
in medicat ion decision making; and (4) develop informatics systems that integrate retail 
pharmacists within the primary care team.   
•  Phase of the trial : 3 
• A description of the type/design of trial to be conducted: This study is a prospective, 2 -arm, trial 
randomizing patients receiving care at p rimary care clinics to Adherence intervention 
(ReachOut) or control .   
• A description of methods to be used to minimize bias : Patient randomization using a computer 
generated allocation is used to minimize selection bias.  
• The number of study groups/arms  and study intervention duration:  The study has 2 arms, 
intervention and control. The minimum  intervention duration is  18 months ( about 6 months of  
accrual of patient  index visit s and a minimum o f 12 months follow up after the index date).  
• Indicate if s ingle  site or multi -site: Single site  
• Name of study intervention (s): ReachOut Adherence Intervention ( clinical decision support plus 
pharmacist outreach ) 
• Name of sub- studies , if any,  included in this protocol : None  
   
4.2 SCIENTIFIC R ATIONALE FOR S TUDY DESIGN  
This trial was originally conceived and approved as a clinic cluster randomized trial of control (usual 
care) versus intervention.  However, the intervention was suspended in March 2020 after one week of implementation  due to COVID -19 pandemic response that resulted in loss of the separation of 
treatment groups. There were c linic closures , decreased office visits, and increase in telehealth care.  
To address concerns related to patient crossover from intervention to control settings  (and vice versa) in 
the ongoing COVID -19 era , the study was transitioned to a patient level randomization that was 
conducted using a computerized allocation by the CDS at the time of an index visit within any of the 28 study clinics.  The main advantage t o the patient level randomization is that no matter what happens 
with clinics closing and opening, provider moving between clinics, and where video encounters take place, the study subjects consi stently receive the ReachOut intervention or usual care witho ut 
crossover. Additionally study p ower increases with the patient- level design compared to a clinic -
randomized design.  The disadvantage to the patient level randomization design, and why it wasn’t the initial choice when t he grant was originally funded,  is concern over clinician contamination due to a 
potential learning effect from the intervention that translates to control patients.  However, the net 
effect of this contamination would be a reduction in the intervention effect which would not undermine 
conclusions if the intervention is found to be effective. Given how the clinical setting changed abruptly 
and unexpectedly due to the COVID -19 pandemic , the advantages of a patient -level study design were 
determined to outweigh the disadvantages and be the m ost appropriate way to complete the study and 
test the hypotheses.  
 
4.3 JUSTIFICATION FOR DO SE 
Not applicable  
 
4.4 END OF S TUDY DEFINITION  
The end date for the study  is defined as 12 months after the last patient index visit during the 6  month 
accrual period.  
5 STUDY POPULATION  
5.1 INCLUSION CRITERIA  
To be  eligible for the study, the patient must have an office visit with a clinician (physician or advanced 
practice provider) within a primary care department (family medicine, internal medicine, combine d 
pediatric/inte rnal medicine) at one of the 28 study clinics within the  HealthPartners Medical Group or 
Park Nicollet care system, and meet all of the following criteria:  
1. Age 18 to 75 years, inclusive. The evidence- based guidelines on which the CDS intervention is bas ed 
are not applicable outside this age range.91  
2. Have a primary care encounter (index visit) at a  selected  clinic .  
 
3. Have a primary care encounter that meets one of or more of the following clinical criteria for care 
goals and medication adherence : 
1. In the 12 months prior to the index visit, most recen t A1C ≥8% AND have  one or more active 
non-insulin glycemic medications on their EMR medication list AND a potential adherence issue 
for one or more of these medications based on the Epic Medication Adher ence score ( e-PDC 
<80%, moderate or high confidence)  
2. Two consecu tive encounters with BP values ≥ 140/90 mm Hg AND one or more BP medications 
on their EMR medication list AND a potent ial adherence issue identified ( e-PDC <80%, 
moderate/high confidence)  
3. Mee t the ACC/AHA criteria listed below for moderate or high -intensity statin use AND a statin 
medication on their EMR medication list AND a potential statin adherence issue identified ( e-
PDC <80% , moderate/high confidence ): 
a. Age >21 with atherosclerotic CV dis ease identified  by a CVD diagnosis on the problem 
list or two or more ICD -10 diagnostic codes in the last 2 years  
b. Aged >21 and LDL >190 mg/d l 
c. Aged 40 to 75 AND diabetes identified by the diagnosis on the problem list or two or 
more ICD -10 diagnostic codes in the last 2 years  
d. Aged 40 to 75 with 10- year CV Risk Score > 7.5%  based on the ACC/AHA 10 -year ASCVD 
risk equation.  
 
5.2 EXCLUSION CRITERIA  
An individual who meets any of the following criteria will be excluded from the s tudy analysis : 
1. Patients enrolled in hospice,  
2. Patients with active cancer or undergoing chemotherapy  
3. Patients with pregnancy  identified  in the last year  
4. Patients without HealthPartners insurance coverage for at least 30 continuous days in  the 12 
months before  or 12 months after the index visit will be excluded from the cost analysis.  
5. For Statin cohort, most recent LDL result < 100 mg/dl in the last  2 years  
 
5.3 LIFESTYLE CONSIDERAT IONS  
Not applicable  
 
5.4 SCREEN FAILURES  
 
Not applicable. There are no screening procedures for this pragmatic trial.  All patients meeting inclusion 
and exclusion criteria in selected study clinics are eligible for the intervention.  
 
5.5 STRATEGIES FOR RECRU ITMENT AND RETENTION  
The study is endorsed by medical leadership and  study clinics included had  leadership approval.  The  
CDS system  has become part of the routine care and workflow for patients in the clinics  and CDS content 
is based on pre -approved evidence based guidelines .  As such , consent is waivered fo r providers and 
patients .   
 Several strategies used successfully in previous studies will be adopted to ensure high use rates of the CDS at the point of care. These include:  
1. Training sessions for clinic staff by webinars (with lunch provided) prior to the onset of the intervention to stress the importance to patients and recommended workflow. Communication to clinic staff and clinic leadership through care system newsletters and direct emails to stress the importance of the intervention to patients and the usefulness to providers.  
2. Reliance of nursing staff rather than providers to print the CDS tools when a BPA pops up during the 
rooming process for patients who meet the study edibility criteria.  
3.  Sending clinic leaders print rate reports at the care system, clinic, and provider levels for rates of 
printing the CDS tools for eligible patients, with a goal of print rates >75%.  
4.  Troubles shooting phone calls and emails to clinic leaders if use rates drop below goal.  
 
For the pharmacist outreach par t of the intervention, we will use a registry system to track outreach 
phone calls from start to completion. We will work with pharmacy leadership to develop strategies to 
improve patient contact rates as needed.   
 
6 STUDY INTERVENTION  
6.1 STUDY INTERVENTION (S) ADMINISTRATION  
6.1.1  STUDY INTERVENTION  DESCRIPTION  
Control:   All cont rol patients  will continue to receive  the basic EMR -linked CDS for management of CV 
risk factors and other chronic conditions.  This CDS has been described in detail in previous publications, 
and includes algorithmically  derived identification of high CV risk patients and prioritized treatment 
suggestions for lipids, BP, glycemic  control, weight, tobacco, and aspirin use based on distance from 
goal, current medications, labs, allergies, and  safety considerations.85,92- 97 The basic CDS does not include 
information on medication adherence .   
Intervention:   For intervention patients , the basic CDS system for CV  risk-factor control is enhanced to 
support a team -based care model that identifies risk of nonadherence,  incorporates  medication 
adherence information into the CDS, creates a registry to direct proactive pharmacist outreach, and 
coordinates action plans (Figure below ).  
Figure 2: Operational Model for Adherence Intervention 
 
 
 
 

To do this, the CDS Web service will combine  EMR -identified medications with e -PDC data . Algorithms 
will identify  poor adherence  using e-PDC score s available within  the Epic EMR at patient encounters . 
When medication adhe rence issues are identified, alert messages will appear on the CDS tools for 
patients and providers . Patients with index visits will be followed -up for 6 months as they continue to 
receive CDS  at subsequent encounters . At 6 months, patient e- PDC as well as clinical outcomes will be 
reevalua ted. 
 
Patients with persistent adherence issues identified are added to a registry that is used by the 
pharmacists to conduct outreach. Pharmacist outreach will be conducted primarily by phone, but in -
person arrangements are also an option.  Pharmacists  conducting outreach will identify themselves to 
patients as part of the care team working with the PCP. The  IMB model described in detail in Section 2.2 
will be the framework for assessing and addressing adherence.  Examples of specific action plans that 
may be  recommended includes education, recommending lower cost alternative medications  or 
combination medications , addressing side  effects, using pill boxes, modifying pill -taking schedules 
and/or using reminder systems, or referrals to MTM  pharmacist servi ces or health educators. 
Pharmacists will be guided by  a script template for the phone outreach that walks them through the IMB 
intervention and data collection. The pharmacists involved will have full read/write access to the EMR in 
full compliance with  HIPAA regulations. They can make medication changes through established care 
protocols  and/or communicate with the  prescriber through secure messaging or phone consultation. 
The date of the pharmacist outreach and actions  that result from the IMB intervention will be 
documented in the EHR and incorporated into subsequent CDS  tools and registries to reflect the new 
patient state.  
From preliminary data collected at these clinics, we expect  that subjects meeting eligibility requirements 
will average 3.5 visit s per year to their PCP. Moreover, others and  we have shown that adherence varies 
within patient over time92,98 -103, and this intervention provides an efficient  and powerful tool for ongoing 
surveillance of adherence for timely identification of lapses in adherence, with  tailored CDS based on 
systematic assessment of IMB factors related to relapses in adherence.  
6.1.2  DOSING AND ADMINISTR ATION  
Not applicable  
 
6.2 PREPARATION/H ANDLING/ STORAGE/ ACCOUNTABILITY  
6.2.1  ACQUISITION AND ACCO UNTABILITY  
Not applicable  
 
6.2.2  FORMULATION, APPEARANCE, PACKAGIN G, AND LABELING  
Not applicable  
 
6.2.3  PRODUCT STORAGE AND STABILITY  
Not applicable  
 
6.2.4  PREPARATION  
Not applicable  
 
 
 
6.3 MEASURES TO MINIMIZE BIAS: RANDOMIZATION  
Patients  are randomly allocated 1:1 through a computer- generated program to either control or 
intervention.  Contamination across intervention arms  is unlikely  because all patients  receive CDS 
interventions based on their arm  assignment. All patients assigned to the study arms  are analyzed based 
on their arm  assignment.    
 
6.4 STUDY INTERVENT ION  COMPLIANCE  
Training  
Intervention pharmacists  will be compensated  to attend a 2 -3-hour training session to learn the IMB 
framework, modules related to the chronic diseases addressed,  interviewing techniques, and how to use 
the registry and EMR tools for tracking outreach attempts and documentation . All training will be 
conducted collaboratively with Goodrich, HealthPartners  and Park Nicollet  pharmacy directors and 
managers and the research  team. The training format will be modeled after succ essful pharmacist 
training programs previously conducted  in our care system by pharmacy leadership for diabetes. 
Training materials will include written materials with  companion online and Web -based modules related 
to the diseases addressed and the IMB int ervention.  Targeted i ndividual follow -up training may be 
provided as needed.  For PCPs and clinic staff, we will conduct luncheon training sessions (providers, 
nurses,  pharmacists, and rooming staff)  either in -person or through webinars  that focus on workflow 
and enhancements to the basic CDS system to  address medication adherence. We will also send 
information through newsletters and communication via email to clinic leaders through the care system 
leadership.  
 
Follow -up 
Rates of PCP us e of the CDS and rates of completed pharmacist outreach will be monitored continuously 
during the study period (through electronic reports) and reported  monthly to clinic and pharmacy 
leadership . If needed to increase use rates and c onsistent with our prev ious successful CDS 
implementation, small incentives ( e.g. $250 per clinic semi- annually) may be provided to clinics whose 
PCPs achieve CDS use rates at >75% of eligible encounters in both intervention and control sites.    
 
The outreach, including the percent of patients with completed outreach contact will also be tracked.  
Per agreement  with the participating pharmacies,  we will provide compensation for time spent  
implementing the outreach . If necessary, trouble shooting with pharmacy leaders and/or supplemental 
training will be provided to pharmacists  with low completed contact rates . While the proposed 
intervention is rooted in the pragmatism of the current health  care world, it is also based on an 
established process -control conceptual model, curren t theories of behavior  change, and our previous 
work on chronic disease prevention and control in the study population.104- 106 
Study Team Monitoring 
Co-Investigators will regularly meet with study staff to discuss study progress and address potential 
issue s. The purpose of these meetings is to focus on the day -to-day operations of the project and to 
assure that all necessary tasks are completed in a timely fashion and strictly according to study protocol. 
Quar terly meetings will include steering group membe rs and will address scientific issues, including 
refinement of conceptual models, strategies to streamline and deploy the interventions efficiently and effectively, and strategies to maximize both recruitment and retention of study subjects, as well as 
methods to assure uniformity and fidelity to intervention protocols and data collection.
 
6.5 CONCOMITANT THERAPY  
Not applicable  
 
6.5.1  RESCUE MEDICINE  
Not applicable  
 
7 STUDY INTERVENTION  DISCONTINUATION  AND PARTICIPANT 
DISCONTINUATION /WITHDRAWAL  
7.1 DISCONTINUATION  OF STUDY INTERVENTION  
This is a minimal risk study without need for halting rules.  The CDS suggestions are evidence -based and 
guideline driven and p roviders are always advised to  exercise their clinical judgement with any CDS 
suggestions.     
 
7.2 PARTICIPANT  DISCONTINUATION /WITHDRAWAL  FROM THE S TUDY  
Providers  and patients  exposed to the clinical decision support can ignore or disregard any component 
of the intervention  at their discretion .  Patients can decline or refuse phone calls from pharmacists. 
Patients who  opt-out of participating in research  will be excluded from the analysis dataset.  
 
7.3 LOST TO F OLLOW- UP 
All eligible patients who are enrolled in the analysis at an index visit will be included in the analysis 
(unless they have opted out of resea rch).  Patients who move, disenroll from the clinic, or have no 
follow up in the clinic will be accounted for through the analytic plan. We anticipate loss to death < 2% and disenrollment from the insurance plan in < 5% per year.   Patients who have opted out of research 
per federal law are excluded from the analysis (<2%). Few patients transfer care between HealthPartners  and/or Park Nicollet  clinics.
 
 
8 STUDY ASSESSMENTS AN D PROCEDURES  
8.1 EFFICACY ASSESSMENTS  
Rates of use of the CDS and rates of completed pharmacist outreach will be monitored continuously during the study period (through electronic reports) and reported monthly to clinic and pharmacy leadership. We will also conduct qualitativ e interviews with  end-users before, during, and after 
intervention implementation to further assess the end user experience and for quality improvement. 
Patient and provider surveys will be conducted post -implementation.  
 
8.2 SAFETY AND OTHER ASSESSMENTS  
 
The CDS too l uses patient information in the electronic medical records to  apply evidence -based 
algorithms that  identify eligible patients, compute  cardiovascular risks, prioritize  cardiov ascular risk 
factors , alert to potential medication issues , provide treatment re commendations, and promote  
adherence assessments and action plans . The study team has extensive experience in health services 
research and clinical research with human subjects, with procedures to safeguard privacy and personal information.  See section 10. 1.3 below on a detailed description of procedures put in place to assess and 
ensure safety of patient information.  
   
8.3 ADVERSE EVENTS AND S ERIOUS ADVERSE EVENTS  
 
8.3.1  DEFINITION OF ADVERS E EVENTS (AE)  
 
AE means any untoward medical occurrence associated with the use of an intervention in humans, 
whether or not considered intervention -related107,108.  
 
8.3.2  DEFINITION OF SERIOU S ADVERSE EVENTS (SA E)  
An AE or suspected adverse reaction is considered "serious" if , in the view of either the investigator or 
sponsor, it results in any of the following outcomes: death, a life -threatening adverse event, inpatient 
hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or subs tantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth 
defect. Important medical events that may not result in death, be life- threatening, or require 
hospitalization may be considered serious when, based upon appr opriate medical judgment, they may 
jeopardize the participant  and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition. Examples of such medical events include severe hypoglycemia  
requiring intensive treatme nt in an emergency room or at home, elevated blood pressure  or convulsions 
that do not result in inpatient hospitalization . 
 
8.3.3  CLASSIFICATION OF AN  ADVERSE EVENT  
8.3.3.1  SEVERITY OF EVENT  
For AEs not included in the protocol defined grading system, the following gui delines will be used to 
describe severity.  
 
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily 
activities.   
• Moderate – Events result in a low level of inconvenience or concern with the therapeutic 
measures. Mod erate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug 
therapy or other treatment. Severe events are usually potentially life -threatening or 
incapacitating.  Of note, the term  “severe” does not necessarily equate to “serious” . 
 
8.3.3.2  RELATIONSHIP TO STUD Y INTERVENTION  
All AEs must have their relationship to study intervention assessed by the clinician who examines and 
evaluates the participant based on temporal relationship and his/her clinical judgment. The degree of certainty abou t causality will be graded using the categories below.  
 
• Related  – The AE is known to occur with the study intervention , there is a reasonable possibility 
that the study intervention caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study intervention and the AE.  
• Not Related  – There is not a reasonable possibility that the administration of the study 
intervention caused the event, there is no temporal relationship between the study intervention 
and event onset, or an alternate etiology has been established.  
 
8.3.3.3  EXPECTEDNESS  
An AE will be considered unexpected if the nature, severity, or frequency of the event is not co nsistent 
with the risk information previously described for the study intervention . 
8.3.4  TIME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP 
 
With DSMB approval, this study will implement a passive surveillance strategy for potential AE’s related to the study intervention .  Data will be analyzed using model- predicted percentages of patients with 
safety conditions of interest for defined time periods during the intervention.  Logistic regression models 
are used to generate predicted proportions by rand omized treatment group controlling for age and 
baseline characteristics .  
  The occurrence of an AE or serious adverse event ( SAE) may  also come to the attention of project team 
members during patient and provider survey results  and interviews with stake h olders . These  AEs not 
meeting the criteria for SAEs will be captured on the appropriate  report forms . Information to be 
collected includes event description, time of onset, clinician’s assessment of severity, relationship to study product (assessed only by  those with the training and authority to make a diagnosis), and time of 
resolution/stabilization of the event. All AEs occurring while on study will be documented appropriately 
regardless of relationship. All AEs will be followed to adequate resolution.  
 
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at each level of severity to be performed. AEs characterized as intermittent require documentation of onset and duration of each episode.   
 
The project  manager, in collaboration with the PI  will record all reportable events with start dates 
occurring any time after inclusion into the study population  until 7 (for non -serious AEs) or 30 days (for 
SAEs) after the last day of study partic ipation.  At each clinic visit, the project team member(s)  will 
inquire about the occurrence of AE/SAEs since the last visit.  Events will be followed for outcome 
information until resolution or stabilization.  
  
8.3.5  ADVERSE EVENT REPORT ING  
According to the HealthPartners Insti tute IRB policies, i nvestigators must report the specified adverse 
events or issues to the IRB as soon as possible, but in no event later than 10 working days after the investigator first learns of the e vent. Investigators or the project team must report p ossible problems or 
issues with the research to the IRB Office in writing using the Unanticipated Problem/Serious Adverse Event Form.  The written report should contain the following: Detailed information about the event or 
issue, including relevant dates; Any corrective and preventative actions, planned or already taken, to ensure that the issue or problem is cor rected and will not occur again; An assessment of whether any 
subjects or others were placed at risk as a result of the event or suffered any harm (e.g., physical, social, financial, legal or psychological) and any plan to address these consequences.  
 
8.3.6  SERIOUS ADVERSE EVEN T REPORTING  
The study investigator shall complete an Unanticipated Adverse Device Effect Form and submit to the study sponsor and to the reviewing Institutional Review Board ( IRB) as soon as possible, but in no event 
later than 10 working days after the investigator first learns of the effect.   
 
8.3.7  REPORTING EVENT S TO PARTICIPANTS  
Participating clinics will be informed of AEs and SAEs through communication with the clinic and 
healthcare group leadership and providers. Although unlikely, if specific patients are affected or at risk, they will be contacted through their routine patien t communication channels and through their 
providers.  
 
8.3.8  EVENTS OF SPECIAL IN TEREST  
Not-Applicable  
 
8.3.9  REPORTING OF PREGNAN CY  
Pregnancy is an exclusion criteria for the study. However, reporting is not warranted as there is no direct harm anticipated from the  study.  
 
8.4 UNANTICIPATED PROBLE MS 
 
8.4.1  DEFINITION OF U NANTICIPATED PROBLEMS (UP) 
 The Office for Human Research Protections ( OHRP ) considers unanticipated problems involving risks to 
participants or others to include, in general, any incident, experience, or outcome that meets ALL  of the 
following criteria:  
 
• Unexpected in terms of nature, severity, or frequency given (a) the research  procedures that are 
described in the protocol -related documents, such as the Institutional Review Board ( IRB)-
approved research protocol and informed consent document; and (b) the characteristics of the 
participant population being studied;  
• Related or pos sibly related to participation in the research (“possibly related” means there is a 
reasonable possibility that the incident, experience, or outcome may have been caused by the 
procedures involved in the research); and  
• Suggests that the research places par ticipants or others at a greater risk of harm (including 
physical, psychological, economic, or social harm) than was previously known or recognized.  
  
8.4.2   UNANTICIPATED PROBLE M REPORTING  
The investigator will report unanticipated problems ( UPs) to the reviewing Institutional Review Board 
(IRB) and t o HealthPartners  Institute108. The UP  report will inc lude the following information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project 
number;  
• A detailed description of the event, incident, experience, or outcome;  
• An explanation of the basis for determining that the event, incident, experience, or outcome 
represents an UP ;  
• A description of any changes to the protocol or other corrective actions that have been taken o r 
are proposed in response to the UP . 
 To satisfy the requirement for prompt reporting, UP s will be reported using the following timeline:   
• UPs that are serious adverse events ( SAEs) will be  reported to the IRB and to the study sponsor 
within 5 days  of the investigator becoming aware of the event.  
• Any other UP  will be reported to the IRB and  the s tudy sponsor within 10 working  days  of the 
investigator becoming aware of the problem.  
• All UPs should be reported to appropriate institutional officials ( as required by an institution’s 
written reporting procedures), the supporting agency head (or designee), and the Office for 
Human Research Protections ( OHRP ) within 1 month  of the IRB’s receipt of the report of th e 
problem from the investigator.  
 
 
8.4.3  REPORTIN G UNANTICIPATED PROB LEMS TO PARTICIPANTS  
Participating clinics will be informed of UPs through communication with the clinic and healthcare group 
leadership and providers. Although unlikely, if specific patients are affected or at risk, they will be conta cted through their routine patient communication channels and through their providers.  
 
9 STATISTICAL CONSIDER ATIONS   
 
9.1 STATISTICAL HYPOTHES ES 
• Primary Efficacy Endpoint(s):  
 For patients 18 to 75 years old not at goal for BP, A1C, or statin use and with medication nonadherence, those randomly assigned to the ReachOut Adherence Intervention will have improved adherence and clinical outcomes compared to those randomly assigned t o control.  
Hypothesis 1.1 Relative to those assigned to  control, eligible adults with uncontrolled BP and baseline 
nonadherence to one or more BP medications who are assigned to intervention will be more likely to 
achieve (a) an e -PDC ≥80% for all BP medications and (b) a reduction in systolic BP in the 12 -month 
period after the index visit.  
Hypothesis 1.2 Relative to those assigned to  control, eligible adults with diabetes and A1C ≥8% and 
baseline nonadherence to a non -insulin glycemic medication who  are assigned  to intervention will be 
more likely to achieve (a) e-PDC ≥80% for all non -insulin glycemic medications and (b) a reduction in A1C 
values in the 12 -month period after the index visit.  
Hypothesis 1.3 Relative to those assigned to  control, eligib le adults with inadequately managed lipid 
disorders with baseline non -adherence to a statin who  are assigned  to intervention will be more likely to 
achieve an e -PDC ≥80% for a statin in the 12 -month period after the index visit.  
 
• Secondary Efficacy Endpoin t(s): 
 Assess the cost and cost -effectiveness of the ReachOut Adherence Intervention from the health 
system (payer) perspective through empirical analysis and microsimulation modeling of patient utilization and disease outcomes.  
Hypothesis 2.1 : Relative to those who are assigned  to control, eligible study subjects who are assigned  
to intervention will have significantly higher overall health care costs in the 12 -month period following 
the index visit, after controlling for demographics and base line clinical risk factors.  
Hypothesis 2.2 : Relative to those who are assigned  to control, eligible study subjects who are assigned  
to intervention will have significantly lower overall resource use and fewer major CV  and diabetes -
related events in a 30 -year post -intervention simulated analysis using cost -effectiveness 
microsimulation modeling methods.  
 
9.2 SAMPLE SIZE  DETERMINATION  
 
H1.1 (BP): Based on prelimin ary data collected in our study clinics between August 6,  2019 and 
December 23, 2019,  we anticipate that 2,132  patients will meet study eligibility criteria of having at 
least one antihypertensive medication with e -PDC <80%  over a 6 -month enrollment period .  For power 
analysis, we adjusted this estimate by half (N=1,066) to conservatively account for a potential 
continuation of the current decrease in office visit secondary to clinic, visit and provider changes as part of COVID -19 pandemic response.  Further assuming a two-sided α=0.05, equal comparison groups (1:1 
intervention/control), and  a probability of outcome (adherence) in the control group of 50% , the 
analysis for H1.1a will have 80% power to detect a difference  in the proportion  of patients with 12 -
month e-PDC ≥80% of 8.7 % or more ( e.g., 50.0% in control patients  vs. 5 8.7% in interv ention patients ). 
For pre -post analyses of SBP outcomes, we estimate that to detect a clinically meaningful difference in 
mean 12 -month SBP of 3 mmHg, assuming 80% power, α =0.05, SD=15.8, 1:1 intervention/control, and 
ρ=0.5 (correlation of repeated measure s), a sample size of N=872 patients will be required.  Given the 
projections described above (N=1,066), we expect sufficient enrollment to meet this target sample size.  
H1.2 (Glycaemia): From preliminary data we estimate that 1,664  patients will meet study eligibility 
criteria due to having at least one non -insulin glucose medication with e -PDC <80% and having a most 
recent A1C ≥8 %. Adjusting this estimate by half (as above) we anticipate N=832. Assuming a two -sided 
α=0.05, equal co mparison groups (1:1 intervention/control), and a probability of outcome (adherence) 
in the control group of 50% , the analysis for H1.2a will have 80% power to detect a difference in the 
proportion of patients with a 12 -month e-PDC ≥80% of 9.9% (e.g., 50.0 % in control patients  vs. 5 9.9% in 
intervention patients ). For pre -post analyses of A1C outcomes, assuming α =0.05, SD=1.7, 1:1 
intervention/control, and ρ =0.5 (correlation of repeated measures), and N=832, we expect 80% power 
to detect a clinically meaning ful difference in A1C of 0.3% (e.g., 9.7% in control patients vs. 9.4% in 
intervention patients).   
H1.3 (Statin use): From preliminary data we estimate that 3, 388 patients will meet study eligibility 
criteria due to having a statin -specific e-PDC <80%. Adjusting this estimate by half we anticipate 
N=1,694. Assuming a two -sided α=0.05, 1:1 intervention/control, and a probability of outcome 
(adherence) of 50% , the analysis for H1.3 will have 80% power  to detect a difference in the proportion 
of pa tients with a 12 -month e-PDC ≥80%  for statin medications of 6.9 % (e.g., 50.0% in control patients  
vs. 5 6.9% in intervention patients ). 
 
9.3 POPULATIONS FOR A NALYSES  
The analysis population is limited to subjects who meet intervention eligibility requirements at an index 
visit. We will use data from the Wizard algorithm runs outside the encounter at 6 and 1 2 months post -
index visit to analyze the impact of the intervention on adhere nce (e -PDC) and clinical outcomes ( A1C, 
BP, statin use) . The cost analysis is limited to the subset of these patients who have HealthPartners 
insurance for at least 11 of 12 months after the index visit .  
 
9.4 STATISTICAL ANALYSES  
 
9.4.1  GENERAL APPROACH  
The primary predictor is the study arm to which a patient  is randomized. This variable is a one -degree-
of-freedom contrast with the control group as the reference category and adherence intervention as the 
other category. Patient and provider characteristics will be documented in order to assess the extent to 
which results apply to subgroups of patients. Patient characteristics obtained from the EMR include 
demographics, health care payer, and comorbid conditions. We will have complete information for 
physician characteristics, including age, years since graduation, sex, full - or part -time work status, and 
physician or allied provider (e.g., nurse practitioner). Pharmacist characteristics will be collected by 
survey.  
 
9.4.2  ANALYSIS OF THE PRIM ARY EFFICACY ENDPOIN T(S)  
Definitions of Dependent Variables (Aim 1): The pri mary dependent variables are described in Table  
3 below .  
 
Table 2 . Description of Dependent Variables Used in Primary and Secondary Analysis.  
Variable  Description  Data Source  Classification  
PDC provided in 
the EMR  (H1.1a, 
H1.2a, H1.3)  For each condition, achievement of e-PDC ≥80% 
for all medication classes for that particular 
condition (diabetes, hypertension, statin 
indication) in the 12 months  following index date.  EMR  Binary  
BP reduction 
(mmHg) (H1.1b)  Mean change in SBP from the last BP within the 
12 months  prior to the index visit, to the last BP 
value within 12 months  after the index visit.  EMR vitals  Continuous  
Change in A1C 
value (H1.2b)  Change in A1C value from the last lab test within 
the 12 mont hs prior to the index visit, to the last 
lab test within 12 months  after the index visit.  EMR 
procedure 
results  Continuous  
 Drug- specific PDCs are extracted from Epic EMR . Key secondary dependent variables (also  defined in 
Table 3) include (a) total 10 -year ACC/AHA CV risk, and ( b) other objective measures of medications 
adherence such as PDC  calculated using claims data, and (c) survey assessed patient self- reported 
adherence using a validated instrument .
110 We will assess  additional dependent variables through a 
patient survey including barriers to adherence,111 shared decision  making,112 health care satisfaction,113 
and provider and pharmacist knowledge, attitudes, beliefs, and satisfaction with the CDS.  
Analysis Plan for Aim 1 (Adherence and Outcome Hypotheses) : Hypotheses H1.1a, H1.2a, H1.3 posit 
that patients assigned to  the adherence intervention will be more likely than patients assigned to usual 
care  to have high medication adherence ( e-PDC ≥80%) in the 12 months  following the index visit for BP 
medications (H1.1a), glucose medications (H1.2a), and statin medications  (H1.3). Generalized linear 
model (GLM) regression with a logit link and binomial error distribution will be used to test  the effect of 
the intervention. The general form of the analytic primary model for testing medication adherence 
is:𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙 (Pr[𝑃𝑃𝑃𝑃𝑃𝑃≥0.8])=𝛽𝛽0+ 𝛽𝛽1(𝐼𝐼𝐼𝐼𝑙𝑙𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑙𝑙𝑙𝑙𝑙𝑙𝐼𝐼)+ 𝛽𝛽𝑐𝑐(𝑃𝑃𝑙𝑙𝐼𝐼𝐶𝐶𝐼𝐼𝑙𝑙𝐶𝐶𝑙𝑙𝐼𝐼𝐶𝐶) 
The dependent variable in each model (antihypertensive medications, glucose -lowering medications, 
statins) is  a binary indicator of high medication adherence ( e-PDC ≥80%) and is predicted by a binary 
indicator of adherence intervention assignment. We will screen and include  patient characteristics in the 
model when they are unbalanced by treatment arm.  In supplemental analyses, we will extend the GLM 
approach described above by including random intercepts to evaluate potential clustering effects at the level of clinic and/or provider.  
 
H1 will be supported if the intervention  group effect β1 is signific ant and positive, supporting the 
prediction  that clinic al encounters  with the adherence intervention are more effective than encounters  
without them for increasing  medication adherence. Treatment group heterogeneity by patient sex, age 
group, race, insuran ce class, and  comorbidity count will be assessed by including interaction terms 
consisting of products of patient variables  and the intervention  indicator.  
Hypotheses H1.1b and H1.2b posit that patients assigned to  the adherence intervention will be more 
likely than control patients to have reduced SBP (H1.1b) and  reduced A1C (H1.2b) in the 12 months 
following the index visit.  
𝐸𝐸(𝑌𝑌)𝑡𝑡= 𝛽𝛽00+𝛽𝛽10(𝐼𝐼𝐼𝐼𝑙𝑙𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑙𝑙𝑙𝑙𝑙𝑙 𝐼𝐼)+𝛽𝛽01(𝑇𝑇𝑙𝑙𝑇𝑇𝐼𝐼)+𝛽𝛽11(𝐼𝐼𝐼𝐼𝑙𝑙𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝑙𝑙𝑙𝑙𝑙𝑙𝐼𝐼∗𝑇𝑇𝑙𝑙𝑇𝑇𝐼𝐼)+
𝛽𝛽𝑐𝑐0(𝑃𝑃𝑙𝑙𝐼𝐼𝐶𝐶𝐼𝐼𝑙𝑙𝐶𝐶𝑙𝑙𝐼𝐼𝐶𝐶)The analytic  model will be a generalized  linear model with an identity link and normal 
error distribution. The  dependent variable Y  (SBP for H1.1b and A1C for H1.2b) is predicted by a binary 
indicator of intervention assignment , time (pre -intervention vs. post), and t he interaction of 
intervention assignment and time. We will screen  and include patient characteristics in the model when 
they are unbalanced by treatment arm , and will evaluate the potential for clustering by clinic and/or 
provider . 
A significant intervention  group -by-time interaction term ( P<0.05) and a pre -specified contrast 
indicating  more reduction in SBP (H1.1b) or A1C (H1.2b) in the intervention  than the control arm will 
support the prediction that  encounters  with the adherence intervention a re more effective than 
encounters  without it for improving BP and glycemic  clinical outcomes.  
Missing Data : All key analytic variables will be derived from EMR or health plan databases in which it is  
extremely rare for care -delivery information to be incom pletely recorded. The primary endpoints for 
differential change in A1C and SBP by study arm will be analyzed  using all available data at multiple time 
periods using direct likelihood -based ignorable methods obtained via  generalized  linear models, with no 
need to model the missing data process, and will yield valid inference  when the outcome is missing at 
random.114,1 15 For H1.1a, H1.2a, H1.3, if preliminary analyses determine that  patient covariates are 
predictive of missing outcome data, we will consider using one or more of the following  strategies. We 
will include these variables as covariates so that the model is conditioned on these  characteristics. We 
will assume that missing values represent failed trials (e.g., a failure to realize one of the  binary  
outcomes), resulting in conservative estimates of intervention effects. Finally, multiple imputation  
procedures may be employed to accurately estimate parameters across multiple imputed data sets.  
9.4.3  ANALYSIS OF THE SECO NDARY ENDPOINT(S)  
 
Definition of Heal th Care Costs: Costs for this analysis include intervention costs and incremental 
medical care costs attributable to the intervention, defined from the health system perspective. Intervention costs include implementation , incentives to maintain high use rates, maintenance, and 
training but exclude  research, development, and measurement costs.
116 Standard micro -cost accounting 
methods and nationally  representative pricing of inputs will be used to measure the cost of the 
intervention. We include clinic  payments to reimburse pharmacist time and resources for conducting 
active outreach. Medical care costs  include the cost of all prescribed medications and clinic services —
including laboratory, MTM pharmacist,  educator, and physician services —incurred in the  12-month pre - 
and post -index date periods by  participants in each study group, as indicated by insurance claims and 
clinical encounter data. Emergency  department visits and hospitalizations may be too infrequent in the 
study sample to accurately predict a population wide impact. To avoid substantially increasing variance 
without adding accuracy to the cost  assessment, we will include emergency department and inpatient 
costs only if a significant difference in these  is observed.  
While market prices generally are a good estimate of the costs for medical services, the paid amount in this claims system is  specific to HP  at a particular time and may provide a biased view of costs  between 
pre- and post -intervention periods. To address this, we will use Total Care  Relative Resource Values
TM 
(TCRRVs), which are a nationally standardized set of measures that have been endorsed by the National 
Quality Forum117 and are derived from Centers for Medicare and Medicaid Services (CMS) relative value 
units (RVUs).  TCRRVs ex tend CMS RVU measures to include utilization categories, such as laboratory 
services and medications, which do not have CMS RVU weights118.  Specifically, TCCRVs defined during 
the midpoint of patient accrual and follow -up (e.g., 2020) will be used to conv ert claims to represent 
U.S. dollars . 
Analytic Plan for Health care costs  (12-month Utiliza tion) :  Incremental medical costs will be estimated 
using standard health  econometric methods. A generalized estimating equation (typically assuming a 
gamma distribution and log link  function) will be used to estimate costs by study arm while controlling 
for demographics and baseline clinical risk factors.119- 121 The marginal effect of being assigned to an 
intervention  clinic will provide an estimate of the in cremental medical cost associated with the 
ReachOut adherence  intervention.  
Definition of Long -term Cost a nd Health Outcomes : Health outcomes include incidence, morbidity, and 
mortality of CV disease (including myocardial  infarction, stroke, congestive hea rt failure, and angina 
pectoris) and microvascular complications due to  diabetes (including blindness, ulcer, first amputation 
with no previous ulcer, first amputation with previous  ulcer, second amputation, and renal failure). 
Medical costs corresponding with the incidence and ongoing management of these conditions are based 
on nationally representative data derived from the Medical Expenditure Panel Survey.122 
Analytic Plan for Long -term Costs and  Outcomes : The Health Partners  Institute ModelHealthTM: A 
cardiovascular disease (CVD)  microsimulation model will be used to estimate long -term outcomes and 
cost-effectiveness from the health  system perspective.123 ModelHealth: CVD is an annual- cycle 
microsimulation model that, in its base  configuration, is parameterized to estimate lifetime CV events 
and disease costs in persons representative of  the U .S. population. The model has been previously used 
to conduct a decision analysis for the U.S. Preventive  Services Task Force recommenda tion on aspirin 
and to evaluate improvements in hypertension, lipid, and  lifestyle management.124-129  
The study population will be simulated at the patient level by assigning the known characteristics of the  
adherence intervention and control groups to sy nthetic counterparts. Age, sex, race/ethnicity, BMI, 
systolic BP,  cholesterol, smoking status, CV disease history, diabetes status, A1C, and medication use for 
persons in each  study group at the end of the study follow -up period will be entered into the mo del 
baseline. Linear,  exponential, logarithmic and, if appropriate, polynomial trends, will be fit to the 
observed intervention  differences in medication adherence, CV risk factors, and A1C (identified by H1.1 -
H.3 and secondary  analyses) and used to project future differential trends between the simulated 
ReachOut adherence  intervention and control groups. Incidence of major CV events will be determined 
using risk equations  developed specifically for the model using Framingham Heart Study data.130,13 1 
Calculation and reporting of incremental cost -effectiveness  ratios (ICERs) will follow the guidelines of 
the Panel on Cost -Effectiveness in Health and  Medicine.132 ICERs will be estimated with a 30 -year 
analytic horizon in the primary analysis, and 10 - and 20 -year horizons will be considered in secondary 
analyses. Sources of uncertainty will be evaluated using  standard sensitivity methods.133 
 
9.4.4  SAFETY ANALYSES  
Trends in  potential  safety concerns for subjects will also be monitored and analyzed as indicated by  the 
Data Safety and Monitoring  plan outlined in the safety oversight section below.   
 
9.4.5  BASELINE DESCRIPTIVE  STATISTICS  
Data extracted will contain patient demographic information including  age, sex and  race.  
 
9.4.6  PLANNED INTERIM ANAL YSES  
Not-applicable  
 
9.4.7  SUB -GROUP ANALYSES  
Assessment of heterogeneity of treatment utilization and effects based on pre -specified  subgroups of 
patients will incorporate a factor (e.g. sex) and its interaction with treatment arm in mixed models.  A 
small number of a priori subgroup variables will be tested and include patient sex, age group, race,  
insurance class (Medicaid, Medicare, commercial), comorbidity count, and pharmacy characteristics . 
 
9.4.8  TABULATION OF INDIVI DUAL PARTICIPANT DATA  
Individual participant  data will not be listed by measure and time point.  
 
9.4.9  EXPLORATORY ANALYSES  
In tertiary/exploratory  analysis, we evaluate the impact of the intervention on 10 -year CV risk , other 
objective measures of medication adherence such as PDC, survey assessed patient self -reported 
adherence, and patient and provid er experience and satisfaction  as assessed by surveys and interviews . 
We will also explore differences in intervention use across patient subgroups based on age, gender , race 
and ethnicity and visit characteristics (such as type of visit, reason for visit, or provider) . Treatment arm 
differences will be assessed using a general or generalized linear mixed -model approach as wit h the 
primary analysis, with link functions and error distributions determined by the distribution of each 
outcome.  
 Patient and provider experience, satisfaction, facilit ators and barriers to implementation w ill be  
evaluated using patient  and provider  surveys and  qualitative  interviews . Throughout the development 
and intervention periods , qualitative interviews with key stakeholders which may include clinic and 
pharmacy leaders, PCPs, clinic staff, pharmacists  and patients  will be conducted to assess end user 
experience, enhance design and maximize buy -in. Qualitative interviews  may be recorded , transcribe d 
and analyzed ethnographically until thematic saturation is achieved .
134 Post -implementation, a 
pharmacist and PCP  surv ey will assess measures of satisfaction, knowledge, use of adherence 
information, and shared decision -making  behaviors.135,136 Patient surveys will be conducted with a 
random sample of about 7 00 intervention and about 7 00 control p atients . The surveys will be conducted 
in 2 phases, the first phase occurring  within 2 to 4 weeks after index visit and the second phase 2  to 4 
weeks after addition to the pharmacist registry  to give ample time for the pharmacist outreach to be  
completed in the intervention subjec ts >=6 months after the index visit. The second survey sample will 
include only patients who responded to a question on the first survey consenting to be called again in 6 months for another survey. Surveys will be conducted in a sequential multimode design to  
simultaneously minimize costs and nonresponse error.
137,138 Surveys will include questions pertaining to 
self- reported  adherence, b arriers to adherence,111 shared decision making,112 satisfaction113, and quality 
of provider communication.139 The patient survey sample size assumes 50%  response rates, consistent 
with those regularly  achieved by HP Center  for Evaluation and Survey Research , and is large enough  to 
show significance based on results observed with these instruments in previous trials conducted by our  
research team and others. Existing scales with known psychometric properties will be used for surveys where  available. Where no existing scales are available, questions will be developed using best practices 
to minimize  measurement erro r.
139 
 
10 SUPPORTING DOCUMENTA TION AND OPERATIONAL  CONSIDERATIONS 
10.1 REGULATORY, ETHICAL , AND S TUDY OVERSIGHT CONSIDERATIONS  
10.1.1 INFORMED CONSENT PROCESS  
10.1.1.1  CONSENT/ASSENT AND O THER INFORMATIONAL D OCUMENTS PROVIDED TO 
PARTICIPANTS 
As with previous CDS studies we have conducted, a waiver of consent for the study population will be 
requested for the following reasons108:  
a) All open treatment medication options identified by the intervention are U.S. Food and Drug 
Administration -approved and evidence -based, as specified  in the regional and national clinical practice 
guidelines. No care is advocated that is not evidence- based.  
Thus, the care conforms to current standards of care and ought not to represent any additional risk to  
patients beyond the routine risk that all pa tients assume whenever they have contact with the medical 
care system.  The CDS system has been used to support diabetes, hypertension and lipid management in 
two previous ly completed  randomized clinical trials with DSMB monitoring that  revealed no safety 
concerns.  
(b) The CDS identifies and gives safety warnings about drug -drug and drug condition  that are potentially 
unsafe to the patient, which is of minimal risk to possible benefit to each patient at  each  visit during the 
study period.  
(c) At clinic train ing sessions /communications  and on printed decision support tools, we  emphasize that 
it is inappropriate for a PCP to follow suggested treatment options without further checking the  clinical 
status of a given patient. A disclaimer on the CDS says that trea tment options are based only on  
electronically available data and are not intended to be a su bstitute for clinical judgment.  
(d) It would be  impractical to consent patients (due to large numbers of patients) and impossible to 
answer the primary  research qu estions (due to selection effects related to consent) if written informed 
consent of all patients were  required.  
(e) Procedures are in place to opt out of pharmacist phone calls based on patient or provider 
preference.   
(f) The intervention is supported b y the care system’s leadership,  implemented with their collaboration 
and support, and embedded in the care process at the clinic and  department level. Therefore, it would 
be accessible to all providers and pharmacists, with use of the tool indicating implied consent.  
 
For the random sample of patients surveyed as part of the study, study information  will be included in 
the survey invitation letter and survey introduction  during the phone call , and implied consent will be 
assumed for survey responders.  Informed consent will be obtained prior to any interviews.  
 
In addition to the internal HealthPartners Institute policies, HIPAA itself makes specific provision for 
waiver of  authorization to use protected health information (PHI) for research recruitment purposes 
under some specific  conditions, all of which this study meets140.  
 
At HealthPartners, patients can opt out of use of their data for research. HealthPartners  Institute keeps 
a record of the small number of individuals who have opted out to avoid u se of their data or attempts to 
recruit them into studies. We will exclude patients from analysis who have declined permission for their medical  records to be used in research.  
 
10.1.1.2  CONSENT PROCEDURES A ND DOCUMENTATION  
Not-applicable.  
10.1.2 STUDY DISCONTINUATIO N AND  CLOSURE  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable 
cause.  Written notification, documenting the reason for study suspension or termination, will be provided by the suspending or terminating party t o participating clinics , investigators, study team 
members and the funding agency .  If the study is prematurely terminated or suspended, the  Principal 
Investigator ( PI) will promptly inform participating clinics , the In stituti onal Review Board ( IRB), and 
sponsor and will provide the reason(s) for the termination or suspension.   
  
Circumstances that may warrant termination or suspension include, but are not limited to:  
• Determination of unexpected, significant, or unacceptable risk to participants  
• Demonstration of efficacy that would warrant stopping    
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
• Determination that the primary endpoint has been met  
• Determination of futility  
 Study may res ume once concerns about safety, protocol compliance, and data quality are addressed , 
and satisfy the sponsor and IRB.  
  
10.1.3 CONFIDENTIALITY AND P RIVACY  
In order to ensure patient confidentiality, we need to print the name of the patient on the CDS tools that are printed and  given to  the patient and their PCP at the time of a clinic visit. Because more than 
one nurse -PCP team may use the same printer, names are required to avoid mixing up printed materials 
and giving PHI to the wrong patient. It is also desirab le to have each patient’s name on this  sheet of 
paper to ensure the patient knows that the information on the paper is personalized and related to his  
or her own health state. The technical aspects of this system are also relevant. The CDS system includes a Web service that applies a complex set of evidence -based algorithms  and requires the patient name to 
create the materials that are subsequently displayed and printed within the EMR.  Several measures are in place to ensure security of PHI : (1) Data  trans fer to and from the EMR, the Web service (at 
HealthPartners Institute), and the Web display (accessed at HealthPartners clinics and pharmacies and 
Goodrich pharmacies) uses a Simple Object Access  Protocol (SOAP) with Secure Sockets Layer (SSL) 
encryption o ver Hypertext Transfer Protocol Secure  (HTTPS); (2) The servers reside on an internal 
network protected by multiple firewalls; and (3) The Web server sits in the demilitarized zone (DMZ) so 
it can communicate with external systems. The rest of the processi ng and data storage occur on servers 
located inside the second firewall. No external system can access these  servers directly, providing 
maximum security to the data that reside on these servers . 
 
Although used for CDS display, patient names are scrubbed f rom the data nightly. The remaining data is  
retained  in the operational data store for 2 weeks for immediate trouble shooting. Later, if needed for 
approved  research, the data is moved to an analytic database with minimal access. With respect to the 
analyt ic databases, the following measures will be taken to protect PCPs and patients from the risk of 
breach of  confidentiality: The patient name is not retained within the analytic database. A unique study 
ID code unrelated  to the medical record number or othe r study subject -specific information will be 
assigned to each patient at the  index visit (first visit in the intervention period). The study ID is used to 
link data from patient encounters over  time and various data sources that are needed for analysis. A 
crosswalk table linking this code number to a PCP or patient name or medical record number will be 
destroyed within 12 months after completion of the linked databases needed to test study hypotheses.  
 
In compliance with HIPAA regulations140, no personally identifiable health information (PHI) will be 
shared outside of the affiliated covered entities (ACE) without obtaining a data use agreement or 
business associates agreement. HealthPartners Institute and HealthPartners are each one component of 
a larger organization defined as an ACE under HIPAA regulations. This allows researchers at the Institute 
to use HealthPartners medical records data for purposes such as those in this study in compliance with 
HIPAA regulations (i.e., following the concept of “minimally necessary” use of PHI).  
The study team has extensive experience in health services research and clinical research with human subjects, with procedures to safeguard privacy and personal information. All study records are protected by: 
• Locked storing all paper records in a secure location  
• Use of untraceable study ID numbers instead of names wherever possible  
• Password protection as well as firewalls  
• Strong user login authentication on all electronic devices  
• Physical security for all electronic d evices containing personal information  
 Data will be retained in secure storage following the completion of the study in accordance with Minnesota and federal law. We guard against the potential for breach of subject confidentiality through 
a multi- layered  system of data protection policies, processes, staff training, software safeguards and 
physical security measures for both paper and electronic data involved in research.  
The following measures will be taken to protect subjects from the risk of breach of confidentiality:  
• All data collected in the study will be identified by using a previously assigned arbitrary and 
unique subject identification number to each participant.  • A file containing a link between the study ID and individually identifying info rmation will be 
maintained at by a programmer who is member of the study team through the conclusion of the 
study.  
• A cross -walk table linking the study ID to a patient identity will be destroyed within  12 months 
after the linked databases needed to test  study hypotheses are completed.  
• All electronic study data will be maintained in a computerized database residing on a 
username - and password -protected file -server to which only the researchers involved in the 
study will have access.  
• All study -relate d paper documents containing individually identifiable information will be 
maintained in locked file cabinets.  
 
To protect the confidentiality of any HealthPartners employees participating in an interview, we will not 
allow anyone outside of the research t eam to know the identity of those interviewed. All of the 
protection to electronic data sources, described above, also apply to the interview audio recordings and 
transcripts.  
 
Certificate of Confidentiality:  
To further protect the privacy of study partic ipants, a Certificate of Confidentiality will be issued by the 
National Institutes of Health (NIH).  This certificate protects identifiable research information from 
forced disclosure. It allows the investigator and others who have access to research records to refuse to disclose identifying information on research participation in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, or local level. By protecting researchers and 
institutions from being compel led to disclose information that would identify research participants, 
Certificates of Confidentiality help achieve the research objectives and promote participation in studies 
by helping assure confidentiality and privacy to participants.  
 
10.1.4 FUTURE USE OF STORED SPECIMENS AND  DATA  
Data collected for this study will be analyzed and stored at the HealthPartners Institute. Data used by 
the CDS is stored at an operational data store for 2 weeks for immediate trouble shooting. Later, if needed for approved research, the data is moved to an analytic database with minimal access. After the 
study is completed, the de -identified, archived data will be transmitted to and stored at the Wizard Data 
Repository , for use by other researchers . 
Sharing of study procedures and outcomes is an essential element of this research proposal.  We are 
determined to ensure that data sharing occurs on a local, regional, and national lev el. Our plan includes 
the following:                 
Local: We will work closely with clinical and administrative leaders at HealthPartners and Park Nicollet to 
ensure that our adherence interventions will be well accepted and locally relevant. During the 
intervention and analysis phases of the project, we will continue to meet with these leaders to update them on our findings. If desired, once the intervention period is complete, we will activate the CDS at all 
HealthPartners and Park Nicollet primary care  clinics in Minnesota and Wisconsin. Findings of our 
research will be presented locally at the HealthPartners Celebration of Research & Education and to 
local clinical and administrative leaders.  
Regional: To ensure statewide availability and dissemination  of results and interventions, Dr. Tom Kottke 
and Steve Simenson are influential regional and national opinion leaders in cardiovascular prevention and care and pharmacy management. In addition, findings of this research will be presented at regional confe rences such as the Minnesota Health Services Research Conference and others. Results will also be 
communicated to the leaders at the Minnesota Department of Health and to other regional and statewide medical groups through the Institute for Clinical System s Improvement, a regional shared -
learning quality -improvement organization of which HealthPartners is a member.   
National: Our main study findings will be presented at national meetings and published in peer -reviewed 
journals. Marsha Raebel, PharmD, forme r Senior Investigator, Kaiser Colorado, a well- recognized 
national expert in the adherence field, will help with national dissemination of our findings. In addition, 
our CDS tool is developed as a Web -based application to facilitate its adoption outside of 
HealthPartners, and the basic CDS has been implemented by three additional care systems. NIH 
research funding obtained in 2017 (R01HL133793) will expand the use of the basic CV CDS tool (without 
adherence information) to safety net clinics within the Unit ed States. The ‘safety net’ community health 
centers (CHCs) serving our nation’s most socioeconomically vulnerable populations are in great need of 
CDS that effectively supports CVD risk management, because CVD risks, incidence, and poor outcomes 
are subst antially higher in CHC patients than the general population. We will offer support to 
operationalize the adherence -based enhancements to care systems that have implemented the basic 
CDS. If the funding agency desires, and if permitted under then -current law, at the conclusion of the 
funding period, we may provide a de -identified data set to the National Heart, Lung and Blood Institute 
at its written request for the use of other qualified researchers in the future.   
 
10.1.5 KEY ROLES  AND STUDY GOVERNANCE  
 
Principal Investigator  Project Manager  
JoAnn M. Sperl -Hillen, MD  
Senior Clinical Investigator  Lilian N. Chumba, MD , MScGH  
Research Project Manager  
HealthPartners Institute  HealthPartners Institute  
8170 33rd Ave S  
Mail Stop 23301A  
Bloomington, MN 55425  8170 33rd Ave S  
Mail Stop 23301A  
Bloomington, MN 55425  
952-967-5009  952-967-5279  
joann.m.sperlhillen@healthpartners.com  lilian.n.chumba@healthpartners.com  
Other Team Members  
Co-Investigators  Patrick O’Connor, Caitlin Frail, Pamala Pawloski  
Statistics and Data Management  Jeffrey Anderson  
Health Economics  Steve Dehmer  
Application Development  Deepika Appana  
 
Consultants : 
The project includes a strong team of external consultants, including nationally recognized experts in 
medication adherence (Marsha Raebel, PharmD,  retired  Senior Investigator, Kaiser Permanente 
Colorado)  and retail pharmacy (Steve Sime nson, President of Goodrich Pharmacy)  
 
Steering group: 
The study team has  a steering group that meets regularly  as needed. It includes the two consultants 
above as well as internal health  plan and medical group leaders.  
 
10.1.6 SAFETY OVERSIGHT  
Safety oversight will be under the direction of a Data and Safety Monitoring Board ( DSMB ) composed of 
individuals with the appropriate expert ise, including expertise in clinical trials  methodology and the 
clinical domains addressed in the proposed research. The member board includes:  Dr. Catherine 
Benziger,  the Medical Director of Heart and Vascular research for Essentia Health, a Cardiologist in the 
Essentia Health Heart and Vascular Center, and an adjunct clinical professor at the Univers ity of 
Minnesota Medical School; Dr. Barry Blumenfeld, a S enior Physician I nformaticist at RTI International 
with more than 25  years of experience in clinical informatics and executive leadership in health care 
information systems design, development, i mplementation, and optimization; Dr. Julian Wolfson , Ph.D, 
an Associate Professor, Division of Biostatistics, School of Public Health, University of Minnesota with 
more than 10 years’ experience in biostatistics including clinical trials; and Dr. David Smith, PharmD, a PhD holder in Pharmaceutical Outcomes Research and Policy working  as a Distinguished Investigator  at 
the Center for Health Research in  Kaiser Pe rmanente Northwest . This well rounded board brings 
expertise in CV disease and diabetes, information technology, and statistical expert ise. In addition, a 
representative of the funding agency, NHLBI, will be invited to participate via conference call at all  
formal DSMB meetings. The PI will participate in the DSMB meetings in a limited way, as recommended in NIH policy.  The DSMB will meet at least semiannually to assess safety and efficacy data on each arm 
of the study. The DSMB  will convene within 3 months  of the intervention  start and will meet twice 
annually throughout the  intervention period.  The DMSB will operate under the rules of an approved 
charter that will be written and reviewed at the organizational meeting of the DSMB. A special focus of interes t will be the safety of patients exposed to the study intervention. With regard to the basic CDS 
(CDS without the adherence information), similar CDS has been provided to PCPs in two previous  NIH-
funded projects by our research team (R01DK068314 and R01HL1 02144), and extensive examination of  
clinical data by those DSMBs has thus far failed to detect any adverse effects of these interventions. The  
ReachOut Adherence intervention provides point -of-care CDS that  provides  medication adherence 
scores and evidenc e-based treatment suggestions to PCPs,  pharmacists, and adults aged 18 -75 years 
with suboptimal A1C, BP, or lipids  consistent with  national guideline  recommendations that have been 
further vetted by clinical leaders at HPMG and Goodrich pharmacies and  outside consultants who have 
agreed to participate in this project. CDS recommendations provided as part of  the ReachOut Adherence 
intervention are designed to support clinicians’ decision -making, not to override  clinical judgment. 
Adverse events informati on will be collected in accordance with DSMB recommendations by  the study 
coordinator and recorded on standard forms based on those used in other trials (R01HL102144).  
Consistent with NIH and HealthPartners IRB policy, all adverse events will be promptly reported in 
writing to the  NIH, the DSMB, and the HealthPartners IRB.  
 
10.1.7 CLINICAL MONITORING  
Not-applicable  
 
10.1.8 QUALITY ASSURANCE AND QUALITY CONTROL  
Quality control ( QC) procedures will be implement ed beginning with routine QC checks on the data 
capture  system.  Any missing data or data anomalies will be communicated to application and epic 
development team s for clarification/resolution.  
The HealthPartners  Institute will provide direct access to all trial related clinics , source data/documents, 
and reports for the purpose of monitoring and auditing by the sponsor, and inspection by local and regulatory authorities.
 
 
10.1.9 DATA  HANDLING  AND RECORD  KEEPING   
10.1.9.1  DATA COLLECTION AND  MANAGEMENT RESPONSIB ILITIES  
 
i. Data sources  
All necessary data to determine eligibility, implement and operate the intervention, test the study hypotheses and assess the impact of the intervention are derived from (a) electronic health records EHRs, (b) health plan or medical group administrative databases, (c) feedback received directly from 
patients and providers by email or through the CDS feedback tab/links (d) surveys of samples of eligible 
patients in both study arms, (e) surveys of participating PCPs and pharmacists, and (f) interview 
transcripts and field notes  
ii. Process steps for data ac quisition  
At each patient encounter in an intervention or control clinic, the CDS Web service will use EPIC 
generated medication adherence scores to  identify potential adherence issues.  Clinical decision support 
generated using the  adherence data will be  presented only at intervention clinics.  At the index visit (the 
first visit in the 1 2-month enrollment period that  study inclusion and exclusion criteria are met), the 
patient is assigned a unique study identifier that is used to  link patient encounter data over time. All 
index and subsequent encounter data for eligible patients, including medications and adherence 
calculations, are securely stored behind a firewall within a limited de -identified  analysis dataset. No 
effort is made to prevent or discourage control clinics from using their usual methods to  assess and 
address medication adherence.  
All data collection conducted is blinded to randomization assignment. We will establish common study variable  definitions drawn from national standards, HEDIS Measurement Sets, and definitions used in 
previous  studies.
141 We will construct variable definitions and data extraction procedures for 
demographics, enrollment  characteristics, vital signs, pharmacy, inpatient and outpatient encounters, 
and diagnoses. We wi ll develop  conceptual and operational definitions and technical specifications for 
data elements without established  definitions. Data from all sources, including encounter data, claims, 
and EMR data, will be restructured into a  common format and data elem ents combined into uniform 
files. A unique identifier will link all person -level  information. Data integrity will be assessed to ensure 
that observations are valid, reliable, and consistent. Each  variable will be tested for completeness and 
out-of-range values. We will create Limited Data Sets that are  consistent with human subjects’ 
protection and HIPAA privacy regulations that will be kept at HP Institute, along  with data dictionaries, 
coding manuals, and other documentation relevant to data collection or  measurement  issues. This 
resource may, subsequent to this study, be available to the funding agency or to other approved  
investigators in accordance with then -current regulations about data privacy and data use.  
 
 
10.1.9.2  STUDY RECORDS RETENT ION  
Study documents will  be retained for a minimum of 2 years  after the last day of data collection . 
 
10.1.10  PROTOCOL DEVIATIONS  
The PI, Dr. JoAnn Sperl -Hillen, will lead weekly meetings of the  investigator team to ensure that all 
project activities are conducted and completed in a  timely fashion and  exactly as specified in the study 
protocol. The team will identify and report any deviations within 5 working days of identification of the 
protocol deviation, or within 5  working days of the scheduled protocol -require d activity.  All d eviations 
will be addressed in study source documents, reported to NHLBI and the Program Official.   Protocol 
deviations will also be sent to the reviewing Institutional Review Board (IRB) per their policies . In 
addition, the programmers will meet weekly to  deal with  operational issues related to development, 
implementation, and maintenance of the intervention tools and with  data and analysis issues 
throughout the project.  
 
10.1.11  PUBLICATION AND DATA  SHARING POLICY  
This study will comply with the NIH Data Sharing Policy and Policy on the Dissemination of NIH -Funded 
Clinical Trial Information and the Clinical Trials Registration and Results Information Submission rule . As 
such,  this trial will be  registered at ClinicalTrials.gov , and results information from this  trial will be 
submitted to ClinicalTrials.gov.  In addition, every attempt will be made to publish results in peer -
reviewed journals.  Data from this study may be request ed by other researchers  3 years after t he 
completion of the primary endpoint or 2 years after the main paper of the trial has been published, whichever comes first , by contacting Dr. JoAnn Sperl -Hillen . 
 
10.1.12  CONFLICT OF  INTEREST  POLICY  
The independence of this study from any actual or perceived influence  is critical.  Therefore , any actual 
conflict of interest of persons who have a role in the design, conduct, analysis, publication, or any aspect of this trial will be disclosed and managed. Furthermore, persons who have a perceived conflict of interest will be required to have su ch conflicts managed in a way that is appropriate to their 
participation in the design and conduct of this t rial.  The study leadership in conjunction with the 
National Heart, Lung, Blood Institute  has established policies and procedures for all study grou p 
members to disclose all conflicts of interest and will establish a mechanism for the management of all reported dualities of interest.  
 
10.2 ADDITIONAL CONSIDERA TIONS  
Not applicable  
 
  
10.3 ABBREVIATIONS  
 
ACC/AHA  American College of Cardiology/American Heart Association  
ACE affiliated covered entities  
AE(s) Adverse Event (s) 
ASCVD  Athersosclerotic cardiovascular Disease  
AWPs  average wholesale prices  
BP Blood pressure  
BPA Best Practice Advisory  
CDS Clinical Decision Support  
CFR Code of Federal Regulations  
CMS  Centers for Medicare & Medicaid Services  
COC  Certificate of Confidentiality  
CONSORT  Consolidated Standards of Reporting Trials  
CPT4  Current Procedural Terminology  version 4  
CRF Case Report Form  
CV Cardiovascular  
DSMB  Data Safety Monitoring Board  
DRE Disease -Related Event  
DRG(s)  diagnostic -related group (s) 
EC Ethics Committee  
eCRF  Electronic Case Report Forms  
EHR Electronic Health Record  
EMR  Electronic Medical Record  
e-PDC Epic provided Proportion of Days Covered  
FDA Food and Drug Administration  
GCP Good Clinical Practice  
HIPAA  Health Insurance Portability and Accountability Act  
HP HealthPartners  
HPMG  HealthPartners  Medical Group  
IB Investigator’s Brochure  
ICD-10 10th revision of the International Statistical Classification of Diseases and Related Health Problems  
ICERs  incremental cost -effectiveness  ratios  
ICH International Conference on Harmonisation  
ID Identification  
IMB Information/Motivation/Beliefs  
IRB Institutional Review Board  
LDL Low-density lipoprotein  
mg/dl  milligrams/deciliter  
mm Hg  Millimeters of Mercury  
MTM  Medication Therapy  Management  
NCT National Clinical Trial  
NIH  National Institutes of Health  
OHRP  Office for Human Research Protections  
PCMH  Patient -centered medical homes  
PCP(s)  Primary Care Provider(s)  
PDC Proportion of Days Covered  
PHI personally identifiable health information  
PI Principal Investigator  
PN Park Nicollet  
QC Quality Control  
RVU(s)  relative value unit (s) 
SAE(s) Serious Adverse Event (s) 
SOA  Schedule of Activities  
SOP Standard Operating Procedure  
UKPDS  United Kingdom Prospective  Diabetes Study  
UP Unanticipated Problem  
US United States  
VA Veterans  Affairs  
WHO  World Health Organization  
 
  
11 REFERENCES  
  
 
References   
 
1. Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence 
across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728- 740. 
2. Cramer JA, Benedict A, Muszbek N, Keskinaslan A, Khan ZM. The significance of 
compliance and persistence in the treatment of diabetes, hypertension and 
dyslipidaemia: a review. Int J Clin Pract. 2008;62(1):76 -87. 
3. Osterberg L, Blaschke T. Adherence to medication. The New England journal of medicine. 2005;353(5):487- 497. 
4. Kennedy J, Tuleu I, Mac kay K. Unfilled prescriptions of medicare beneficiaries: 
prevalence, reasons, and types of medicines prescribed. J Manag Care Pharm. 
2008;14(6):553 -560. 
5. Pladevall M, Williams LK, Potts LA, Divine G, Xi H, Lafata JE. Clinical outcomes and 
adherence to medications measured by claims data in patients with diabetes. Diabetes 
Care. 2004;27(12):2800- 2805.  
6. Lage MJ, Hassan MK. The relationship between antipsychotic medication adherence 
and patient outcomes among individuals diagnosed with bipolar disorder: a retrospective 
study. Ann Gen Psychiatry. 2009;8:7.  
7. Turner BJ, Hollenbeak C, Weiner MG, Ten Have T, Roberts C. Barriers to adherence 
and hypertension control in a racially diverse representative sample of elderly primary 
care patients. Pharmacoepidemiology and drug safety. 2009;18(8):672 -681. 
8. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with 
osteoporosis therapy on fracture rates in actual practice. Osteoporos Int. 
2004;15(12):1003 -1008.  
9. Sokol MC, McGuigan KA, Verb rugge RR, Epstein RS. Impact of medication adherence 
on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521- 530. 
10. Noens L, van Lierde MA, De Bock R, et al. Prevalence, determinants, and outcomes of 
nonadherence to imatinib therapy in pati ents with chronic myeloid leukemia: the 
ADAGIO study. Blood. 2009;113(22):5401 -5411.  
11. Ganesan P, Sagar TG, Dubashi B, et al. Nonadherence to imatinib adversely affects 
event free survival in chronic phase chronic myeloid leukemia. American journal of 
hematology. 2011;86(6):471- 474. 
12. World Health Organization (WHO). Adherence to Long -term Therapies: Evidence for 
Action.  
http://www.who.int/chp/knowledge/publications/adherence_report/en/index.html . 
Accessed March 2, 2017.  
13. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical 
treatment outcomes: a meta- analysis. Med Care. 2002;40(9):794 -811. 
14. Stern M. Diabetes in Hispanic Americans. National Diabetes Data Group, eds. Diabetes 
in America, 2nd ed.  Vol 95- 1468. Bethesda, MD: N ational Institute of Diabetes and 
Digestive and Kidney Diseases; 1995:631 -660. 
15. Dragomir A, Cote R, White M, et al. Relationship between adherence level to statins, clinical issues and health -care costs in real -life clinical setting. Value Health. 
2010; 13(1):87 -94. 
16. Hiligsmann M, Rabenda V, Bruyere O, Reginster JY. The clinical and economic burden 
of non -adherence with oral bisphosphonates in osteoporotic patients. Health Policy. 
2010;96(2):170 -177. 
17. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY. Potential clinical and 
economic impact of nonadherence with osteoporosis medications. Calcified tissue 
international. 2010;86(3):202- 210. 
18. Heisler M, Choi H, Rosen AB, et al. Hospitalizations and deaths among adults with 
cardiovascular disease who underuse medications because of cost: a longitudinal 
analysis. Med Care. 2010;48(2):87 -94. 
19. Breitscheidel L, Stamenitis S, Dippel FW, Schoffski O. Economic impact of compliance 
to treatment with antidiabetes medication in type 2 diabetes mellitus : a review paper. 
Journal of medical economics. 2010;13(1):8- 15. 
20. Simpson SH, Eurich DT, Majumdar SR, et al. A meta- analysis of the association 
between adherence to drug therapy and mortality. Bmj. 2006;333(7557):15.  
21. Rasmussen JN, Chong A, Alter DA.  Relationship between adherence to evidence- based 
pharmacotherapy and long- term mortality after acute myocardial infarction. Jama. 
2007;297(2):177 -186. 
22. Bryant LJ. Medicines adherence-- evidence for any intervention is disappointing. Journal 
of primary h ealth care. 2011;3(3):240 -243. 
23. Nease B, Miller S, Frazee SG, et al. 2010 Drug trend report: A market and behavior analysis. St. Louis, MO: Express Scripts;2011.  
24. Thinking outside the pillbox: A system -wide approach to improving patient medication 
adherence for chronic disease. A NEHI Research Brief -  August 2009 2009; 
http://www.nehi.net/writable/publication_files/file/pa_issue_brief_final.pdf . 
Accessed March 2, 2017.  
25. Senst BL, Achusim LE, Genest RP, et al. Practical approach to determining costs  and 
frequency of adverse drug events in a health care network. Am J Health Syst Pharm. 
2001;58(12):1126 -1132.  
26. McCarthy R. The price you pay for the drug not taken. Business and health. 
1998;16(10):27 -28, 30, 32- 23. 
27. McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug 
reactions. Ann Pharmacother. 2002;36(9):1331 -1336.  
28. Sabate E. Adherence to long- term therapies: evidence for action, World Health 
Organization. 2003.  
29. American Colle ge of Preventive Medicine. Medication Adherence Time Tool: Improving 
Health Outcomes. 2011; http://www.acpm.org/?MedAdherTT_ClinRef , May 18, 
2016.  
30. Roth MT, Ivey JL, Esserman DA, Crisp G, Kurz J, Weinberger M. Individualized 
medication assessment and pl anning: optimizing medication use in older adults in the 
primary care setting. Pharmacotherapy. 2013;33(8):787 -797. 
31. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid- lowering medications: a 
cross- national study. Jama. 1998;279(18):1458- 1462. 
32. DiMatteo MR, Giordani PJ, Lepper HS, Croghan TW. Patient adherence and medical treatment outcomes: a meta- analysis. Medical Care. 2002;40(9):794- 811. 
33. Cramer J. Partial medication compliance: the enigma in poor medical outcomes. Am J 
Manag Care. 1995;1:45- 52. 
34. Hughes D, Cowell W, Koncz T, Cramer J. Methods for integrating medication 
compliance and persistence in pharmacoeconomic evaluations. Value Health. 
2007;10(6):498 -509. 
35. Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient 
outcomes. Curr Hypertens Rep. 2000;2(6):510- 514. 
36. Ayoade A, Oladipo I. Evaluation of the correlation between self -report and electronic 
monitoring of adherence to hypertension therapy. Blood pressure. 2012;21(3):161- 166. 
37. Gonzalez JS, Schneider HE. Methodological issues in the assessment of diabetes 
treatment adherence. Curr Diab Rep. 2011;11(6):472- 479. 
38. Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy 
administrative databases: a proposal for standard definitions and preferred measures. 
Ann Pharmacother. 2006;40(7 -8):1280- 1288.  
39. Raebel MA, Schmittdiel J, Karter AJ, Konieczny JL, Steiner JF. Standardizing terminology and definitions of medication adherence and persistence in research 
employing electronic databases. Med Care. 2013;51(8 Suppl 3):S11- 21. 
40. Vollmer WM, Xu M, Feldstein A, Smith D, Waterbury A, Rand C. Comparison of 
pharmacy -based measures of medication adherence. BMC health services research. 
2012;12:155.  
41. Epic cor poration. How it works: How is Medication Adherence Determined? Epic 2018  
42. Steiner JF. Rethinking adherence. Annals of internal medicine. 2012;157(8):580 -585. 
43. Hudon E, Beaulieu MD, Roberge D. Integration of the recommendations of the Canadian 
Task Force on Preventive Health Care: obstacles perceived by a group of family 
physicians. Fam Pract. 2004;21(1):11 -17. 
44. Tarn DM, Heritage J, Paterniti DA, Hays RD, Kravitz RL, Wenger NS. Physician communication when prescribing new medications. Arch Intern Med. 
2006;166(17):1855 -1862.  
45. Solberg LI, Engebretson KI, Sperl -Hillen JM, O'Connor PJ, Hroscikoski MC, Crain AL. 
Ambulatory care quality measures for the 6 aims from administrative data. Am J Med 
Qual. 2006;21(5):310- 316. 
46. Stewart K, George J, Mc Namara KP, et al. A multifaceted pharmacist intervention to 
improve antihypertensive adherence: a cluster -randomized, controlled trial (HAPPy trial). 
J Clin Pharm Ther. 2014;39(5):527- 534. 
47. Tsuyuki RT, Houle SK, Charrois TL, et al. Randomized Trial of the Effe ct of Pharmacist 
Prescribing on Improving Blood Pressure in the Community: The Alberta Clinical Trial in Optimizing Hypertension (RxACTION). Circulation. 2015;132(2):93 -100. 
48. Giberson S, Yoder S, Lee MP. Improving Patient and Health System Outcomes through 
Advanced Pharmacy Practice. A Report to the U.S. Surgeon General. In: Pharmacist 
OotC, ed: U.S. Public Health Service; 2011.  
49. Maynard RA, Wagner ME, Winkler SR, Montuoro JL. Assessment of student pharmacists' perceptions on participating in clinical  services in the community pharmacy 
setting. Curr Pharm Teach Learn. 2011;3(2):123 -136. 
50. Margolis KL, Asche SE, Bergdall AR, et al. Effect of home blood pressure telemonitoring 
and pharmacist management on blood pressure control: a cluster randomized cl inical 
trial. Jama. 2013;310(1):46- 56. 
51. Santschi V, Chiolero A, Colosimo AL, et al. Improving blood pressure control through 
pharmacist interventions: a meta -analysis of randomized controlled trials. Journal of the 
American Heart Association. 2014;3(2): e000718.  
52. Bunting BA, Smith BH, Sutherland SE. The Asheville Project: clinical and economic 
outcomes of a community -based long- term medication therapy management program for 
hypertension and dyslipidemia. J Am Pharm Assoc (2003). 2008;48(1):23 -31. 
53. Reinke T. Medication therapy management program in N.C. saves $13 million. Manag 
Care. 2011;20(10):17- 18. 
54. Fera T, Bluml BM, Ellis WM. Diabetes Ten City Challenge: final economic and clinical results. J Am Pharm Assoc (2003). 2009;49(3):383- 391. 
55. Svarstad BL, Kotchen JM, Shireman TI, et al. Improving refill adherence and 
hypertension control in black patients: Wisconsin TEAM trial. J Am Pharm Assoc (2003). 
2013;53(5):520 -529. 
56. Pringle JL, Boyer A, Conklin MH, McCullough JW, Aldridge A. The Penns ylvania Project: 
pharmacist intervention improved medication adherence and reduced health care costs. 
Health Aff (Millwood). 2014;33(8):1444 -1452.  
57. Joint Pharamacists Association. Medicare Program; Merit -Based Incentive Payment 
System and Alternative Payment Model Incentive under the Physician Fee Schedule, 
and Criteria for Physician- Focused Payment Models; Proposed Rule. In: Services CfMM, 
ed2016.  
58. Kucukarslan SN, Hagan AM, Shimp LA, Gaither CA, Lewis NJ. Integrating medication 
therapy management in the primary care medical home: A review of randomized 
controlled trials. Am J Health Syst Pharm. 2011;68(4):335- 345. 
59. Centers for Medicare & Medicaid Services. Transforming Clinical Practice Initiative. 
2016; https://innovation.cms.gov/initiatives/Transforming- Clinical- Practices/ . 
Accessed March 2, 2017.  
60. Newport F. Gallup Politics. Congress Retains Low Honesty Rating. 2012; 
http://www.gallup.com/poll/159035/congress -retains -low-honesty -rating.aspx . 
Accessed  March 2, 2017.  
61. Pharm D. Pharmacy Facts & Tools -  Pharmacy Careers Summary.  
http://www.uspharmd.com/student/facts_about_pharmacist/ . Accessed February 3, 
2014.  
62. Feldstein AC, Smith DH, Perrin N, et al. Improved therapeutic monitoring with several 
interventions: a randomized trial. Arch Intern Med. 2006;166(17):1848 -1854.  
63. Vora J. Access to a Health System's Electronic Medical Record. Pharmacy Times. 2015. 
http://www.pharmacytimes.com/publications/health- system -
edition/2015/september2015/access -to-a-health- systems- electronic -medical -
record . Accessed March 2, 2017.  
64. American Pharmacists Association. Walgreens pharmacists begin using EHR's. 2014; 
http://www.pharmacist.com/walgreens -pharmacists -begin- using- ehrs . Accessed 
March 2 2017.  
65. Downard S , Galt KA, Reel AB. Pharmacists' use of electronic health records: Silent 
leaders no more. J Am Pharm Assoc (2003). 2007;47(6):680.  
66. Lau B, Overby CL, Wirtz HS, Devine EB. The association between use of a clinical 
decision support tool and adherence to monitoring for medication- laboratory guidelines 
in the ambulatory setting. Appl Clin Inform. 2013;4(4):476- 498. 
67. Bright TJ, Wong A, Dhurjati R, et al. Effect of clinical decision -support systems: a 
systematic review. Annals of internal medicine. 2012;157(1):29 -43. 
68. McKibbon KA, Lokker C, Handler SM, et al. The effectiveness of integrated health 
information technologies across the phases of medication management: a systematic 
review of randomized controlled trials. Journal of the American Medical Infor matics 
Association : JAMIA. 2012;19(1):22 -30. 
69. Cleveringa FG, Gorter KJ, van den Donk M, van Gijsel J, Rutten GE. Computerized 
decision support systems in primary care for type 2 diabetes patients only improve 
patients' outcomes when combined with feedback on performance and case 
management: a systematic review. Diabetes Technol Ther. 2013;15(2):180- 192. 
70. Kawamoto K, Houlihan CA, Balas EA, Lobach DF. Improving clinical practice using clinical decision support systems: a systematic review of trials to identify features critical 
to success. BMJ. 2005;330(7494):765- . 
71. Derose SF, Green K, Marrett E, et al. Automated outreach to increase primary 
adherence to cholesterol -lowering medications. JAMA internal medicine. 
2013;173(1):38 -43. 
72. Dixon BE, Alzeer  AH, Phillips EO, Marrero DG. Integration of Provider, Pharmacy, and 
Patient -Reported Data to Improve Medication Adherence for Type 2 Diabetes: A 
Controlled Before- After Pilot Study. JMIR Med Inform. 2016;4(1):e4.  
73. Fisher WA, Fisher JD, Harman J. The In formation- Motivation- Behavioral Skills Model: A 
General Social Psychological Approach to Understanding and Promoting Health Behavior. In: Suls J, Wallston KA, eds. Social Psychological Foundations of Health and 
Illness . Malden, MA, USA: Blackwell Publishin g Ltd; 2003.  
74. Goodell LS, Pierce MB, Amico KR, Ferris AM. Parental information, motivation, and 
behavioral skills correlate with child sweetened beverage consumption. J Nutr Educ 
Behav. 2012;44(3):240 -245. 
75. Gao J, Wang J, Zhu Y, Yu J. Validation of an information- motivation- behavioral skills 
model of self -care among Chinese adults with type 2 diabetes. BMC Public Health. 
2013;13:100.  
76. Schmaling KB, Blume AW, N A. A randomized controlled pilot study of motivational 
interviewing to change attitudes about adherence to medications for asthma. J Clin 
Psychol Med Settings. 2001;8:167 -172. 
77. Fisher JD, Fisher WA, Misovich SJ, Kimble DL, Malloy TE. Changing AIDS risk behavior: 
effects of an intervention emphasizing AIDS risk reduction information, motivat ion, and 
behavioral skills in a college student population. Health Psychol. 1996;15(2):114- 123. 
78. Carey MP, Maisto SA, Kalichman SC, Forsyth AD, Wright EM, Johnson BT. Enhancing 
motivation to reduce the risk of HIV infection for economically disadvantaged urban 
women. Journal of consulting and clinical psychology. 1997;65(4):531 -541. 
79. Bandura A. Social Foundations of Thought and Action: A Social Cognitive Theory.  NJ: 
Prentic Hall; 1986.  
80. Lazarus RS. Coping with the stress of illness. WHO Reg Publ Eur Ser. 1992;44:11 -31. 
81. Folkman S. Personal control and stress and coping processes: a theoretical analysis. 
Journal of personality and social psychology. 1984;46(4):839 -852. 
82. Prochaska JO, Velicer WF. The transtheoretical model of heal th behavior change. Am J 
Health Promot. 1997;12(1):38 -48. 
83. Newman S, Steed L, Mulligan K. Self -management interventions for chronic illness. 
Lancet. 2004;364(9444):1523- 1537.  
84. Adult Meducation: Improving Medication Adherence in Older Adults. Dimension 5: 
Patient -Related Factors.  
http://www.adultmeducation.com/patientrelatedfactors_2.html . Accessed May 13, 
2016.  
85. Gilmer TP, O'Connor PJ, Sperl -Hillen JM, et al. Cost -Effectiven ess of an Electronic 
Medical Record Based Clinical Decision Support System. Health services research. 
2012.  
86. O'Connor PJ, Crain AL, Rush WA, Sperl -Hillen JM, Gutenkauf JJ, Duncan JE. Impact of 
an electronic medical record on diabetes quality of care. An n Fam Med. 2005;3(4):300 -
306. 
87. Roshanov PS, Fernandes N, Wilczynski JM, et al. Features of effective computerised 
clinical decision support systems: meta -regression of 162 randomised trials. BMJ 
(Clinical research ed). 2013;346:f657.  
88. Rothman RL, DeW alt DA, Malone R, et al. Influence of patient literacy on the 
effectiveness of a primary care- based diabetes disease management program. Journal 
of the American Medical Association. 2004;292(14):1711 -1716.  
89. Dewalt DA, Berkman ND, Sheridan S, Lohr KN, Pi gnone MP. Literacy and health 
outcomes: a systematic review of the literature. Journal of general internal medicine. 
2004;19(12):1228 -1239.  
90. O'Connor AM, Llewellyn- Thomas HA, Flood AB. Modifying unwarranted variations in 
health care: shared decision mak ing using patient decision aids. Health affairs (Project 
Hope). 2004;Suppl Variation:VAR63- 72. 
91. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering 
implementation of health services research findings into practice: a consolidated 
framework for advancing implementation science. Implementation science : IS. 
2009;4:50.  
92. Desai JR, Sperl- Hillen JM, O‘Connor PJ. Patient preferences in diabetes care: 
overcoming barriers using new strategies. Journal of Comparative Effectiveness 
Research. 2013;2(4):351 -354. 
93. Kharbanda EO, Nordin JD, Sinaiko AR, et al. TeenBP: Development and Piloting of an 
EHR- Linked Clinical Decision Support System to Improve Recognition of Hypertension 
in Adolescents. EGEM S (Wash DC). 2015;3(2):1142.  
94. O'Connor P. Opportunities to Increase the Effectiveness of EHR -Based Diabetes Clinical 
Decision Support. Appl Clin Inform. 2011;2(3):350- 354. 
95. O'Connor PJ, Desai JR, Butler JC, Kharbanda EO, Sperl -Hillen JM. Current stat us and 
future prospects for electronic point -of-care clinical decision support in diabetes care. 
Curr Diab Rep. 2013;13(2):172 -176. 
96. O'Connor PJ, Sperl -Hillen JM, Rush WA, et al. Impact of Electronic Health Record 
Clinical Decision Support on Diabetes C are: A Randomized Trial. Ann Fam Med. 
2011;9(1):12 -21. 
97. Sperl -Hillen JM, Averbeck B, Palattao K, Amundson J, Rush B, PJ OC. Outpatient EHR -
Based Diabetes Clinical Decision Support That Works: Lessons Learned From 
Implementing Diabetes Wizard. Diabetes S pectrum. 2010;23(3):150- 154. 
98. Ruggiero L, Prochaska JO. Readiness for change: application of the transtheoretical 
model to diabetes. Diabetes Spectrum. 1993;6(1):21- 60. 
99. Ruggiero L, Rossi JS, Prochaska JO, et al. Smoking and diabetes: readiness for c hange 
and provider advice. Addict Behav. 1999;24(4):573- 578. 
100. Prochaska J, Velicer W, Rossi J, et al. Stages of change and decisional balance for 12 problem behaviors. Health Psychol. 1994;13(1):39 -46. 
101. Boyle R, O'Connor P, Pronk N, Tan A. Stages o f change for physical activity, diet, and 
smoking among HMO members with chronic conditions. Am J Health Promot. 1998;12(3):170 -175. 
102. Peterson KA, Hughes M. Readiness to change and clinical success in a diabetes educational program. J Am Board Fam Prac t. 2002;15(4):266 -271. 
103. Wubben DP, Vivian EM. Effects of pharmacist outpatient interventions on adults with 
diabetes mellitus: a systematic review. Pharmacotherapy. 2008;28(4):421- 436. 
104. Glasgow RE. RE -AIMing research for application: ways to improve evidence for family 
medicine. Journal of the American Board of Family Medicine : JABFM. 2006;19(1):11 -
19. 
105. Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering 
implementation of health services research findings into practice: a consolidated 
framework for advancing implementation science. Implementation science : IS. 
2009;4:50.  
106. Wagner EH. Chronic disease management: what will it take to improve care for chronic 
illness? Eff Clin Pract. 1998;1(1):2 -4. 
107. Gliklich RE, Dreyer NA, Leavy MB, editors. Registries for Evaluating Patient Outcomes: A User's Guide [Internet]. 3rd edition. Rockville (MD): Agency for Healthcare Research 
and Quality (US); 2014 Apr. 12, Adverse Event Detection, Processing, and 
Reporting . Available from: https://www.ncbi.nlm.nih.gov/books/NBK208615/  
108.  Kelly McCormick. HealthPartners Institute IRB Policies and procedures. Available from  
https://sites.healthpartners.com/hp/InstiNet/irb/SiteAssets/SitePages/Home/IRB%20SOP
s.pdf  
109. Cent ers for Medicare & Medicaid Services. Medicare 2016 Part C &  D Star Rating 
Technical Notes.  https://www.cms.gov/Medicare/Prescription- Drug -
Coverage/PrescriptionDrugCovGenIn/Downloads/2016- Technical -Notes -Preview -1-
v2015_08_05.pdf . Accessed March 2, 2017.  
110. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self -reported 
measure of medication adherence. Med Care. 1986;24(1):67 -74. 
111. Risser J, Jacobson TA, Kripalani S. Development and psychometric evaluation of the 
Self-efficacy fo r Appropriate Medication Use Scale (SEAMS) in low -literacy patients with 
chronic disease. J Nurs Meas. 2007;15(3):203 -219. 
112. O'Connor AM. Validation of a decisional conflict scale. Med Decis Making. 
1995;15(1):25 -30. 
113. Agency for Healthcare Research and Quality. Preparing a Questionnaire Using the 
CAHPS Health Plan Survey 4.0. Rockville, MD. 2007.  
114. Beunckens C, Molenberghs G, Kenward MG. Direct likelihood analysis versus simple 
forms of imputation for missing data in randomized clinical trials. Clin Trials. 
2005;2(5):379 -386. 
115. Little RJA, Rubin DB. The Analysis of Social Science Data with Missing Values. 
Sociological Methods Research. 1989;18(2- 3):292- 326. 
116. Gold M, Siegel J, Russell L, Weinstein M, eds. Cost -Effectiveness in Health and 
Medi cine.  New York: Oxford University Press; 1996.  
117  National Quality Forum. Press release: NQF Endorses Resource Use Measures. January 31, 
2012; 
http://www.qualityforum.org/News_And_Resources/Press_Releases/2012/NQF_Endorses_Reso
urce_Use_Measures.aspx. Acc essed June 12, 2018.  
118. HealthPartners. Total Care Relative Resource Value (TCRRVTM): A Measurement Approach to 
Achieve the Triple Aim. HealthPartners White Paper.  September 21, 2017; 
https://www.healthpartners.com/ucm/groups/public/@hp/@public/documents/documents/cntrb_0
39627.pdf. Accessed June 12, 2018.  
119. Blough DK, Madden CW, Hornbrook MC. Modeling risk using generalized linear models. 
J Health Econ. 1999;18(2):153 -171. 
120. Manning WG, Mullahy J. Estimating log models: to transform or not to transform? J 
Health Econ. 2001;20(4):461- 494. 
121. Kung Yee L, Zeger S. Longitudinal data analysis using generalized linear models. 
Biometrika. 1986;73(1):13- 22. 
122. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. 2001-
2010; http://meps.ahrq.gov/mepsweb/ . Accessed March 2, 2017.  
123. HealthPartners Institute for Education and Research. ModelHealth Microsimulation 
Models. 2015.  https://www .healthpartners.com/hprf/modelhealth/index.html . Accessed 
March 2, 2017.  
124. Dehmer SP, Maciosek MV, Flottemesch TJ, LaFrance AB, Whitlock EP. Aspirin for the 
Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision 
Analysis for the U.S. Preventive Services Task Force. Annals of internal medicine. 2016.  
125. Dehmer SP, Maciosek MV, Flottemesch TJ. Aspirin Use to Prevent Cardiovascular 
Disease and Cancer: A Decision Analysis. AHRQ Publication No. 15 -05229- EF-1. 
Rockville, MD: Agency for Healthcare Research and Quality: AHRQ; 2015.  
126. Maciosek MV, LaFrance AB, Dehmer SP, et al. Updated priorities among effective 
clinical preventive services. Annals of Fam Med. 2017;15(1):14 -22. 
127. Dehmer SP, Maciosek MV, LaFrance AB, TJ F. Health Benefits and Cost -Effectiveness 
of Asymptomatic Screening for Hypertension and Hi gh Cholesterol and Aspirin 
Counseling for Primary Prevention. Annal of Fam Med. 2017;15(1):23- 36. 
128. Dehmer SP, Baker -Goering MM, Maciosek MV, et al. Modeled Health and Economic 
Impact of Team -Based Care for Hypertension. Am J Prev Med. 2016;50(5 Suppl 1):S34 -
44. 
129. Dehmer SP. The economics of a new health technology: an evaluation of the impact of 
statins on lifestyle behaviors . Minneapolis, MN, University of Minnesota; 2012.  
130. Gorelick PB, Mazzone T. Plasma lipids and stroke. J Cardiovasc Risk. 199 9;6(4):217 -
221. 
131. Tight blood pressure control and risk of macrovascular and microvascular complications 
in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ. 
1998;317(7160):703 -713. 
132. Gold M, Siegel J, Russell L, Weinstein M. Cost Effectiveness in Health and Medicine.  
Oxford University Press; 1996.  
133. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model 
parameter estimation and uncertainty analysis: a report of the ISPOR -SMDM Modeling 
Good Research Practic es Task Force Working Group- 6. Med Decis Making. 
2012;32(5):722 -732. 
134.  Lewis, S. (2015). Qualitative Inquiry and Research Design: Choosing Among Five 
Approaches.  Health Promotion Practice , 16(4), 473–
475. https://doi.org/10.1177/1524839915580941  
135. Scholle SH, Pawlson LG, Solberg LI, et al. Measuring practice systems for chronic 
illness care: accuracy of self -reports from clinical personnel. Joint Commission journal 
on quality and patient safety / Joint Commission Resources. 2008;34(7):407- 416. 
136. Solberg LI, Crain AL, Tillema J, Scholle SH, Fontaine P, Whitebird R. Medical home 
transformation: a gradual process and a continuum of attainment. Ann Fam Med. 
2013;11 Suppl 1:S108- 114. 
137. De Leeuw ED. To Mix or Not to Mix Data Collection Modes in Surveys. Journal of Official 
Statistics. 2005;21(2):233- 255. 
138. Dillman DA, Smyth JD, Christin LM. Internet, Mail and Mixed- Mode Surveys: The Tailor 
Design Method.  Hoboken, NJ: Wiley & Sons; 2009.  
139. Agency for Healthcare Research and Quality. CAHPS Clinici an & Group Surveys 
https://cahps.ahrq.gov/Surveys -Guidance/CG/index.html . Accessed October 31, 2014.  
140.  HIPPA Privacy Rule and Its Impacts on Research 
http://privacyruleandresearch.nih.gov/pr_08.asp#8c   
141. National Committee for Quality Assurance. HEDIS Technical Measurement 
Specifications.  
http://www.ncqa.org/HEDISQualityMeasurement/HEDISMeasures/HEDIS2014.aspx . 
Accessed October 31, 2014.  
 